

FORM PTO 1390 (REV. 5-93) US DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY DOCKET NUMBER 2001_0116A
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. §371		U.S. APPLICATION NO. (if known, see 37 CFR 1.10) NEW 09/7762230
International Application No. PCT/JP99/04197	International Filing Date August 4, 1999	Priority Date Claimed August 5, 1998
Title of Invention GENE PARTICIPATING IN THE PRODUCTION OF HOMOGLUTAMIC ACID AND ITS USE		
Applicant(s) For DO/EO/US Tadashi FUJII, Takao NARITA, Kuniho NAKATA, Hitosi AGEMATU, Hiroshi TSUNEKAWA, Kunio ISSHIKI and Takeo YOSHIOKA		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. §371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. §371. 3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. §371(c)(2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) 6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. §371(c)(2)). ATTACHMENT A 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. §371(c)(3)). <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19. 9. <input checked="" type="checkbox"/> An executed oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)). ATTACHMENT B 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)). 		
Items 11. to 14. below concern other document(s) or information included:		
11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. ATTACHMENT C		
12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.		
ATTACHMENT D		
13. <input type="checkbox"/> A FIRST preliminary amendment.		
<input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.		
14. <input checked="" type="checkbox"/> Other items or information: Cover letter (ATTACHMENT E) with 4 deposit receipts and their Verification of Translation.		

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEE FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975.

U.S. APPLICATION NO. (if applicable) ^{37 CFR 1.5} NEW 09/762230	INTERNATIONAL APPLICATION NO. PCT/JP99/04197	ATTORNEY'S DOCKET NO. 2001_0116A
15. [X] The following fees are submitted		CALCULATIONS PTO USE ONLY
BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee nor international search fee paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.00 International Search Report has been prepared by the EPO or JPO \$ 860.00 International preliminary examination fee not paid at USPTO but international search paid to USPTO \$ 710.00 International preliminary examination fee paid to USPTO but claims did not satisfy provisions of PCT Article 33(1)-(4) \$ 690.00 International preliminary examination fee paid at USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$ 100.00		
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$860.00
Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$
Claims	Number Filed	Number Extra
Total Claims	-20 =	X \$18.00
Independent Claims	- 3 =	X \$80.00
Multiple dependent claim(s) (if applicable)		+ \$270.00
TOTAL OF ABOVE CALCULATIONS =		\$860.00
[] Small Entity Status is hereby asserted. Above fees are reduced by 1/2.		\$
SUBTOTAL =		\$860.00
Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		+ \$
TOTAL NATIONAL FEE =		\$860.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +		\$40.00
TOTAL FEES ENCLOSED =		\$900.00
		Amount to be refunded \$
		Amount to be charged \$
a. [X] A check in the amount of <u>\$900.00</u> to cover the above fees is enclosed. A duplicate copy of this form is enclosed. b. [] Please charge my Deposit Account No. 23-0975 in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. [] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 23-0975.		
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.		
19. CORRESPONDENCE ADDRESS		By: <u>Warren Cheek</u> Warren M. Cheek, Jr., Registration No. 33,367 WENDEROTH, LIND & PONACK, L.L.P. 2033 "K" Street, N.W., Suite 800 Washington, D.C. 20006 Phone: (202) 721-8200 Fax: (202) 721-8250 February 5, 2001
[CHECK NO. <u>41844</u>] [2001_0116A]		



JC19 Rec'd PCT/US01/07207
PCT 25 MAY 2001
BOX 562

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Tadashi Fujii et al. : Docket No. 2001-0116A

Serial No. 09/762,230 : Group Art Unit Not Yet Assigned

Filed February 5, 2001 : Examiner Not Yet Assigned

GENE PARTICIPATING IN THE
PRODUCTION OF HOMOGLUTAMIC
ACID AND ITS USE

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEES FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents,
Washington, D.C. 20231

Sir:

Responsive to the Notification of Missing Requirements dated March 29, 2001, please amend the above-identified application as follows:

In the Specification:

Page 1, line 1, delete the entire heading.

line 6, replace the heading with the following new headings:

Background of the Invention

1. **Field of the Invention**

line 14, replace the heading with the following new heading:

2. **Description of the Related Art**

Page 3, line 16, replace the heading with the following new heading:

Summary of the Invention.

Page 5, line 7, replace the heading with the following new heading:

Brief Description of the Drawings.

Page 6, line 25, replace the heading with the following new heading:

Description of the Preferred Embodiments.

Page 26, replace the paragraph beginning at line 28 with the following paragraph:

Analysis of N-terminus amino acid sequence of the band subjected to the blotting was carried out by Edman degradation method using HP G1005A Protein Sequencing System (HEWLETT PACKARD). As a result, it was revealed that the N-terminus amino acid sequence was

SLLAPLAPLRAHAGTRLTQG (SEQ ID NO: 7).

Based on this, DNA primers

NmaRout CCYTGIGTIARICKIGTICCIIGCRTGIGCICG (SEQ ID NO: 8).

NmaRin CCIGCRTGIGCICGIARIGGIGCIARIGGIGC (SEQ ID NO: 9).

were designed, and PCR was carried out on the genome DNA of E. lutescens IFO 3084 strain using LA PCR in vitro cloning KIT (Takara Company). The PCR reaction condition was 30 cycles of 94°C, 30 seconds→55°C, 2 minutes→72°C, 1 minute. As a result, a PCR amplification fragment of about 400 bp containing the above terminus and its upstream region was obtained. Based on this sequence, its neighborhood region was obtained by using PCR. Namely, the genome DNA of E. lutescens IFO 3084 strain was digested with restriction enzymes PstI and

Sall, respectively, and the digests were subjected, respectively, to self-ligation reaction using Ligation Kit version 2 (Takara Company), and the resulting DNAs were used as template DNAs.

Based on these template DNAs, DNA primers

NIFout ttgatttgag cagattcgca ctgccattt (SEQ ID NO: 3)

NIRout aaggtttcg acaaagtgc cattccca (SEQ ID NO: 4)

were designed, and PCR was carried out using LA Taq (Takara Company). The PCR reaction condition was 30 cycles of 98°C, 20 seconds~68°C, 6 minutes. As a result, a PCR amplification fragment of about 2 kbp was obtained from the PstI template and a PCR amplification fragment of about 8 kbp from the Sall template. The base sequence was determined by the primer walking method using ABI PRISM 377XL DNA Sequencer (Perkin Elmer corporation) on these PCR amplification fragments. This base sequence is shown in SEQ ID NO: 1.

In the Abstract:

Page 34, line 1, replace the heading with the following new heading

ABSTRACT OF THE DISCLOSURE.

In The Sequence Listing:

Please replace the Sequence Listing of record with the attached substitute Sequence Listing.

REMARKS

Favorable consideration is respectfully requested in view of the foregoing amendments and the following remarks.

The foregoing amendments are presented to place the application in compliance with the sequence rules under 37 CFR 1.821-1.825.

Applicants have submitted a Sequence Listing in both paper and computer readable form as required by 37 C.F.R. 1.821(c) and (e). Amendments directing its entry into the specification have also been incorporated herein. The content of the paper and computer readable copies are the same and no new matter has been added.

Additional amendments to the specification have also been effected to put the specification in better form under U.S. practice. Specifically, the specification headings have been amended in conformance with U.S. practice.


With regard to the indication that an executed Oath and Declaration of the Inventors has not yet been submitted, Applicants wish to note that an executed Oath and Declaration was submitted with the application papers when the application was filed on February 5, 2001. A copy of the submitted executed Declaration is enclosed herewith along with the Transmittal letter and Postcard receipt (both indicating the filing of the executed Declaration). Applicants respectfully request that the Patent Office review the application papers filed February 5, 2001 to ensure that the executed Declaration is present in the file.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "Version with markings to show changes made."

In view of the foregoing, it is believed that each requirement set forth in the Notice has been satisfied, and that the application is now in compliance with the sequence rules under 37 CFR 1.821-1.825. Accordingly, favorable examination on the merits is respectfully requested.

Respectfully submitted,

Tadashi Fujii et al.

By: 

Lee Cheng
Registration No. 40,949
Attorney for Applicants

LC/gtn
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
May 25, 2001

11/19/05

09/762230

JC05 Rec'd PCT/PTO 05 FEB 2001

1

DESCRIPTION

GENE PARTICIPATING IN THE PRODUCTION OF HOMOGLUTAMIC ACID AND ITS USE

5

Technical Field

This invention relates to gene manipulation, and more specifically, relates to a DNA containing a gene participating in the production of L-homoglutamic acid (also referred to as L-2-amino-10 adipic acid or L- α -amino adipic acid), and a production system of L-homoglutamic acid (hereinafter, merely referred to as homoglutamic acid) using it.

Background Art

15 Homoglutamic acid is found widely in organisms such as plants including Cholera vibrio as a bacterium and corn (Zea mays), the embryos of frogs. Homoglutamic acid acts as an intermediate of lysine biosynthesis in fungi, etc. and as a precursor in biosynthesis of β -lactam antibiotics. Further, homoglutamic acid is also useful as a 20 synthetic intermediate of various medicines including methotrexate derivatives (WO 92/09436).


Since preparation of homoglutamic acid by chemical synthesis needs optical resolution and multistage reaction, it is not a useful means from the aspect of costs. On the other hand, a process 25 of preparing homoglutamic acid from L-lysine using a microorganism belonging to the genus Agrobacterium, Klebsiella, Alcaligenes, Brevibacterium or Bacillus is known (Japanese Laid-open Patent Publication No. 6-181787). Part of the present inventors also proposed a process of preparing homoglutamic acid from L-lysine using a micro-30 organism belonging to the genus Flavobacterium (WO 96/ 31616). However, even in the process using such a microorganism, a process

capable of preparing homoglutamic acid more efficiently is desired earnestly.

Thus, the present inventors aimed to reinforce the production system of homoglutamic acid in any of the above microorganisms, for example by gene manipulation. When a review of helpful information is made on the manipulation, for example, as part of researches of biosynthetic pathway of cephamicin C, are confirmed the presence of lysine-6-aminotransferase and L- Δ^1 -piperidine-carboxylate dehydrogenase participating in conversion from L-lysine to α -amino-10 adipic acid (or homoglutamic acid) of Streptomyces clavuligerus as a cephamicin C-producing actinomycetes, and as to the former, the presence position of the gene encoding the enzyme, etc. (Fuente et al., Biochem. J. (1997) 327, 59-64).

As to Flavobacterium lutescens (which was re-identified 15 from Flavobacterium fuscum) IFO 3084 used in bioassay of L-lysine, it is known that 2-oxoglutarate 6-aminotransferase [or lysine 6-aminotransferase (hereinafter also referred to as LAT)] catalyzing the following pathway is present (Soda et al., Biochemistry 7 (1968), 4102-4109, ibid. 4110-4119).

20



In the above bioassay, the absorbance of the product 30 obtained by reacting piperidine-6-carboxylic acid (hereinafter, also

referred to as P6C) with o-aminobenzaldehyde is measured. In another bioassay of L-lysine, the L-lysine 6-dehydrogenase activity of Agrobacterium tumefaciens is utilized (Misono et al., J. Biochem. (Tokyo) 105 (1989), 1002-1008).

5 The above IFO 3084 strain is commonly used in bioassay of L-lysine as mentioned above, and its use method is also established. Therefore, if the IFO 3084 strain had a gene encoding a protein having P6C (or, the 2-amino adipic acid semialdehyde which is said to be in a quantitatively equilibrium state with P6C in a living body) de-
10 hydrogenase (hereinafter, also merely referred to as dehydrogenase) activity, in addition to LAT, the strain would be a candidate bacterium for gene cloning meeting the object of the present invention, namely the object to provide a gene participating in the production of homoglutamic acid.

15

Disclosure of Invention

15 The present inventors have tried cloning of the lysine-6-aminotransferase (LAT) gene (lat) of Flavobacterium lutescens and, according to circumstances, a gene encoding a protein having de-
20 hydrogenase activity on P6C of the bacterium. However, as cloning methods regularly used for such a case, a method of obtaining a targeted gene from DNA consensus sequences between aminotransferases of other bacteria, and a method utilizing information obtained from the result of amino acid sequencing of a purified protein, and the like have all failed in their early researches.

25 However, unexpectedly, they have found that when the host-vector system finally selected by the inventor is used, a gene at least capable of participating in the production of homoglutamic acid, more specifically a gene encoding a protein having dehydrogenase activity on P6C can be cloned by shotgun cloning. They have also

found that a modifier having a certain homology (or identity) to the gene also functions similarly.

On the other hand, the above Soda et al., Biochemistry 7 (1968), 4110-4119 discloses a process of obtaining crystalline LAT of a 5 molecular weight of 116,000 from Achromobacter liquidum (= Flavobacterium lutescens), and Yagi et al., J. Biochem. 87 (1980), 1395-1402 discloses that LAT from Flavobacterium lutescens is composed of four nonidentical subunits of A, B1, B2 and C. Their early 10 researches of cloning a gene encoding a protein having LAT activity utilizing the information obtained from the amino acid sequencing of the purified LAT protein, based on these descriptions, have failed. However, using a process entirely different from the processes described in these prior art references, the present inventors have purified proteins having LAT activity from Flavobacterium lutescens, 15 have determined the amino acid sequences of the obtained proteins, and have cloned the objective genes utilizing these sequence informations, and as a result they have succeeded in cloning a gene encoding LAT (lat). The invention is based on the above findings.

Thus, according to the invention is provided an isolated 20 pure DNA containing a gene participating in the production of homoglutamic acid which gene can be obtained from a bacterium belonging to the genus Flavobacterium lutescens, or a modifier which hybridizes with the gene under a stringent condition and has a function capable of recovering the homoglutamic acid-producing ability of a mutant 25 which lacks the producing ability.

More specifically, the gene participating in the production 30 of homoglutamic acid is a DNA encoding partly or wholly at least one protein selected from the group consisting of a protein having LAT activity and a protein having dehydrogenase activity, or a modifier thereof.

The invention also relates to an autonomously replicative or integration replicative recombinant plasmid carrying the DNA, and a transformant obtained by transformation with the recombinant plasmid, and a process of producing homoglutamic acid using the 5 transformant.

Brief Description of Drawings

Figure 1 is a drawing showing the analytical results by thin layer chromatography of homoglutamic acid production by mutants of 10 *F. lutescens*. St is standard homoglutamic acid (HG), Lanes 1 to 4, Lanes 5 to 7, Lanes 8 to 10, Lane 11, and Lanes 12 and 13 show the analytical results of the first mutants, the second mutants, the third mutants, the wild type strain and the first mutants having plasmid pCF704, respectively.

15 Figure 2 is a graph showing the lysine 6-aminotransferase (LAT) activity of mutants of *F. lutescens*. Wild, 1st, 2nd and 3rd show the LAT activities of the wild type strain, the first mutant, the second mutant and the third mutant, respectively.

20 Figure 3 shows the results of analyses by thin layer chromatography showing complementarity of homoglutamic acid productivity of homoglutamic acid productivity-lacking mutants by plasmid pCF213.

25 HG and Lys show the moved position of homoglutamic acid and the moved position of L-lysine, and St; 1st pCF213, 2nd pCF213 and 3rd pCF213; Wild pCF213 and Wild pCF704; 1st pCF704 and 2nd pCF704; and 1st pCF111 are the results of TLC analyses of homoglutamic acid standard substance; culture broths of the first, the second and the third mutants having pCF 213, respectively; culture broths of wild type strains having pCF 213 and pCF 704, respectively; 30 culture broths of the first and second mutants having pCF 704,

respectively; and culture broths of the first mutant having pCF 111; respectively.

Figure 4 is a graph showing the productivity of homoglutamic acid with time lapse of *F. lutescens* IFO 3084 (pCF213) (in the drawing, represented by pCF213) and *F. lutescens* IFO 3084 (pCF704) (in the drawing, represented by pCF704).

Figure 5 is a graph showing the presence position ORF found based on the base sequence of the pCF213 insert region.

Figure 6 is a graph showing relations between the elution fractions by the MonoQ HR5/5 column treatment in 3(6) of Example 2 and the relative LAT activities.

Figure 7 is a photograph in place of a drawing showing the results of Native PAGE (A) and SDS-PAGE (B) of the LAT active fractions using Multigel 4/20 and 10/20, in 3(7) of Example 2. In the drawing, M is a molecular weight marker, C represents the ultrafiltrate obtained in 3 (5) of Example 2, and the figures represent the respective fraction numbers.

Figure 8 is a graph showing relative LAT activities in homoglutamic acid productivity-lacking mutants and wild type strains by various plasmids.

Figure 9 is a graph showing the productivity of homoglutamic acid with time lapse of *F. lutescens* IFO 3084 transformed with various plasmids.

25 **Specific Embodiments of Invention**

As to origins of genes according to the invention, any strains of *Flavobacterium lutescens* (hereinafter, also referred to as *F. lutescens*) including spontaneous mutants so long as they can provide a gene participating in the production of homoglutamic acid which gene can be expressed, for example, in *F. lutescens* as a host.

However, mentioned as preferred is the IFO 3084 strain which is easy to obtain and whose suitable handling conditions such as culture are established.

The gene participating in the production of homoglutamic acid in the invention means any gene capable of participating in the two-stage conversion system from L-lysine to homoglutamic acid via P6C or 2-amino adipic acid-6-semialdehyde which is chemically in an equilibrium relation with P6C (the former stage: LAT activity, the latter stage: dehydrogenase activity). First of all, as specific examples of genes encoding a protein having dehydrogenase activity which is the latter conversion system, there can be mentioned genes which can be obtained using the host-vector system established by the present inventors based on the following strategy.

Establishment of a suitable host-vector system of E. lutescens is necessary for carrying out the gene manipulation of E. lutescens, but therefor it is needed to solve the following three problems.

- (1) Obtain a replicon which can autonomously replicate in F. lutescens.
- 20 (2) Obtain a drug resistance marker which can be expressed and function in F. lutescens.
- (3) Establish a method of introducing a DNA into E. lutescens.

Fortunately, the above problems (1) and (2) could be solved by finding that pBBR122, lately put on the market by Mo Bi Tec corporation, which autonomously replicates in a wide range of Gram-negative bacteria and has kanamycin and chloramphenicol resistance can be used. For solution of the above problem (3), first, it becomes a prerequisite that a method of introducing the plasmid pBBR122 into F. lutescens is established. However, examination was

made based on the method of DNA introduction into E. coli by the electroporation method, as a result a colony of F. lutescens grew in an L plate containing 20 µg/ml kanamycin, and by liquid culturing this and extracting plasmids by the alkali SDS method, it was confirmed

5 that pBBR122 was stably held in F. lutescens. Thus, the problem (3) was also solved. As to this host-vector system, it has itself been known that when other bacteria were used as a host, (a) transformation efficiency is very high and (b) a DNA fragment of a suitable size can be inserted into pBBR122 (J. Bac. 178 (1996), 1053- 1060), but it

10 was revealed that the above (a) and (b) are possible also in F. lutescens, and further it was made possible to amplify the obtained gene in F. lutescens, and more over, it was also made possible to obtain a gene encoding a protein having dehydrogenase activity on P6C by shotgun cloning. For facilitating the operation, pCF704 in which the

15 multicloning site of pUC19 was introduced in place of the chloramphenicol resistance gene of pBBR122 was prepared, and this was then used as a vector.

Then, in order to establish a system for evaluating an obtained and amplified gene, mutation was induced in F. lutescens

20 IFO 3084 with N-methyl-N'-nitro-N-nitrosoguanidine (NTG), and screening was made using an MEM plate (pH 7.0) containing eosin Y.

Thus, the first mutant not producing homoglutamic acid at all, and the second and third mutants only slightly producing homoglutamic acid were obtained. In the first mutant not producing

25 homoglutamic acid at all, lat activity equal to the wild type strain was confirmed, and in the second and third mutants only slightly producing homoglutamic acid, only slight lat activity was confirmed. Namely, there is a possibility that the first mutant is suffering some injuries to gene(s) other than lat participating in the production of homoglutamic acid, and on the other hand the second and third mutants

30

are suffering some injuries at least to lat.

Then, the genome DNA of the wild type strain was partly digested with SauIII_{AI}, and the 6-8 kbp fragments were inserted into the BamHI site of pCF704, respectively, to prepare a DNA library.

5 These plasmids were introduced into the first, second and third mutants, respectively, and strains which recovered homoglutamic acid-producing ability were screened. In this occasion, a method was used which comprises collecting colonies blackened in a MEM plate (pH 7.0) containing eosin Y, used for the screening of the mutants,

10 and confirming homoglutamic acid-producing ability thereof by TLC. As representable ones of these mutants, the second mutant (Flavobacterium lutescens 2nd mutant) was deposited on July 6, 1998 with National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, and has been assigned an accession number of FERM P-16874, and the first mutant (Flavobacterium lutescens 1st mutant) was deposited on June 10, 1999 with the Institute, and has been assigned an accession number of FERM P-17419, and these strains are kept there. These FERM P-16874 strain and FERM P-17419 strain were transferred on July 26, 1999 on their

15 deposition to the international deposition authority on Budapest Treaty in the Institute, and have been assigned accession numbers of FERM BP-6798 and FERM BP-6799, respectively.

20

As a result, a strain having a plasmid complementing the productivity of homoglutamic acid of the first mutant and a strain

25 having a plasmid partly complementing the productivity of homoglutamic acid of the second mutant were obtained. However, the plasmids of these strains, particularly plasmid of the strain complementing the second mutant were liable to be deleted, and further screening for obtaining a stable plasmid has been needed. As a result

30 of DNA fragment analysis with restriction enzyme treatment, it was

revealed that the thus obtained plasmid designated pCF111 which complements the first mutant and partly complements the second mutant and the plasmid designated pCF213 were apparently quite the same plasmid.

5 On the other hand, pCF111 and pCF213 were re-transformed into the first, second and third mutants, respectively, and homoglutamic acid-producing ability was checked. As a result, both plasmids complemented the first mutant, but only partly complemented the second and third mutant.

10 Based on the complementation test, it was revealed that in a plasmid sufficiently recovering the homoglutamic acid-producing ability of a homoglutamic acid productivity-lacking mutant, a gene participating at least in the production of homoglutamic acid, more specifically some gene other than lat is present.

15 Thus, not limited thereto, but as one of the "genes participating in the production of homoglutamic acid", there can be mentioned a gene which is contained in the insert part of plasmid pCF213 and encoding a protein having dehydrogenase activity. For example, this gene is present in the sequence shown in SEQ ID NO: 2.

20 On the other hand, a gene participating in the former conversion, namely encoding a protein having LAT activity according to the invention can be cloned as follows.

25 F. lutescens is cultured under a certain culture condition, the obtained strain is fractured, the fracture dispersion is centrifuged to remove the fractured cells, and from the thus obtained cell extract, the desired protein is isolated and purified by ultracentrifugaztion treatment, ammonium sulfate precipitation, desalting, ion exchange column chromatography, affinity column chromatography, ultrafiltration, electrophoresis, etc.

30 From the analytical results of the N-terminus amino acid

sequence of the purified protein, DNA primers are designed, and PCR is carried out on the genome DNA of *E. lutescens* (IFO 3084) strain. Based on the DNA fragment amplified by PCR further PCR is carried out, and thereby the neighborhood region of both outer sides of the 5 DNA fragment is obtained. Thus, a DNA encoding the desired protein of the invention is obtained.

Thus, it becomes possible to provide a DNA encoding a protein having LAT activity as another gene participating in the production of L-homoglutamic acid. Namely, as another gene of the 10 invention, there can, for example, be mentioned one having a sequence composing the coding region of the base sequence of SEQ ID NO: 1. The N-terminus of the corresponding purified protein is Ser as shown in SEQ ID NO: 1, but it is considered that N-terminal Met is processed after translation.

15 Further, the DNA containing a gene participating in the production of homoglutamic acid according to the invention includes a DNA containing at least one each of the gene encoding a protein having dehydrogenase activity and the gene encoding a protein having LAT activity.

20 In addition, the gene referred to in the invention also includes a modifier of both above genes which has a base sequence hybridizing with one of both genes under a certain hybridization condition, for example, under a stringent condition, at 60°C in 2×SSC (in standard citric acid saline), preferably at 60°C in 0.5×SSC, particularly preferably at 60°C in 0.2×SSC, and has a function capable of 25 recovering the homoglutamic acid-producing ability of a mutant of *E. lutescens* lacking the producing ability.

More specifically, a modifier of a gene encoding a protein having dehydrogenase activity is one showing at least 70 % of identity 30 with the base sequence of from base 2855 to base 4387 in SEQ ID NO:

2, and a modifier of a gene encoding a protein having LAT activity is one showing at least 50 %, preferably 70 %, more preferably 95 % of identity with the base sequence of from base 545 to base 2658 (coding region) in SEQ ID NO: 1.

5 Such modifiers include one wherein base(s) is/are removed or added or part of the bases is replaced with other base(s), at the 5'-terminus or 3'-terminus or halfway of one of both the above sequences. The modifier wherein part of the bases is replaced with other base(s) also includes a modifier which encodes the same protein
10 but has a base sequence different from those of both the above genes because of degeneracy of genetic code.

It is recommended to make the substitution of base other than substitution followed by degeneracy of genetic code, considering estimated amino acid sequences encoded by both the above genes, so
15 as to have a similar shape as the whole of protein, based on similarity of the side chain of each amino acid, for example hydrophobicity, hydrophilicity, charge, size, etc. Thus, a modifier having a function equal to the function of one of both the above genes, namely a function capable of recovering the homoglutamic acid-producing ability of
20 a mutant of *F. lutescens* which lacks the producing ability will be obtained in a considerably high probability.

The modifier according to the invention can be synthesized using a nucleic acid synthesizer or prepared by per se known point mutagenesis or site-directed mutagenesis, considering the base
25 sequences of both the above genes or estimated amino acid sequences encoded by them.

According to the invention, a recombinant plasmid carrying the above gene or modifier can also be provided. Such a plasmid can be autonomously replicative one containing, besides the above gene or
30 modifier, an autonomously replicative sequence, a promoter se-

quence, a terminator sequence, a drug resistance gene, etc. Further, the plasmid can be integration type plasmid containing a sequence homologous to a certain region of the genome of the host intended to be used. As an example of the autonomously replicative recombinant 5 plasmid carrying a DNA containing a gene encoding a protein having dehydrogenase activity, there can be mentioned a plasmid pBBR122, or one comprising plasmid pBBR122 having inserted in a certain site thereof a multicloning site or having substituted a multicloning site for the certain site or region and having inserted the above gene or 10 modifier using the multicloning site. As specific examples of such plasmids, there can be mentioned ones designated plasmids pCF111 and pCF213 in the specification. pCF213 can be obtained by a per se known plasmid isolation method from Flavobacterium lutescens IFO 3084 (pCF213) which was deposited on March 11, 1998 with National 15 Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, and has been assigned an accession number of FERM P-16699, and then transferred to international deposition on Budapest Treaty, and has been assigned an accession number of FERM BP-6797. A recombinant plasmid carrying a DNA containing a 20 gene encoding a protein having LAT activity and a recombinant plasmid carrying a DNA containing both genes can also be constructed in the same manner as in the pCF213.

According to the invention, there can further also be provided a transformant obtained by transforming a bacterium 25 belonging to the genus Flavobacterium as a host with the above recombinant plasmid. As the host bacterium belonging to the genus Flavobacterium, any strain of any species can be used so long as it meets the object of the invention, but as preferred ones, there can be mentioned F. lutescens IFO 3084 and F. lutescens SP.7-1 (FERM 30 BP-5457).

Thus, as a specific example of the above transformant, there can be mentioned one obtained by transforming F. lutescens IFO 3084 or F. lutescens SP.7-1 with pCF213, and F. lutescens IFO 3084 (pCF213) is deposited as the FERM BP-6797 with the international deposition authority of National Institute of Bioscience and Human Technology.

According to the invention, a process of producing homoglutamic acid using the transformant is also provided. In the process, the transformant in a medium grown by culture is contacted with

10 L-lysine or in some case P6C (or 2-amino adipic 6-semialdehyde) as a starting material, or the starting material is contacted with a grown transformant or treated cells thereof (e.g., cells treated with an organic solvent, a cell extract, immobilized treated cells) to convert the starting material to homoglutamic acid.

15 As carbon sources of the medium, any carbon sources can be used so long as they are utilizable by the transformant, and when F. lutescens is used as a host, there can, for example, be used saccharides such as glucose, fructose, sucrose and dextrin, sugar alcohols such as glycerol and sorbitol, and organic acids such as fumaric acid

20 and citric acid, and it is desirable that the addition amount of these carbon sources is, usually, on the order of 0.1 to 10 % by weight (hereinafter, abbreviated as %).

As nitrogen sources of the medium, there can, for example, be used ammonium salts of inorganic acids such as ammonium chloride, ammonium sulfate and ammonium phosphate, ammonium salts of organic acids such as ammonium fumarate and ammonium citrate, and further natural nitrogen sources such as meat extract, yeast extract, corn steep liquor and casein hydrolyzate, and it is desirable that the addition amount of these nitrogen sources is, usually, on the

25 order of 0.1 to 10 %.

As inorganic salts, there can, for example, be used alkaline metal salts of phosphoric acid such as potassium phosphate and sodium phosphate, alkaline metal chlorides such as potassium chloride and sodium chloride, and metal salts of sulfuric acid such as 5 magnesium sulfate and ferrous sulfate, and it is desirable that the addition amount of these inorganic salts is, usually, on the order of 0.001 to 1 %.

Among them, liquid culture using a usual growth medium for bacteria is preferred, and glucose, maltose, starch, etc., as carbon 10 sources and ammonium sulfate, peptone, yeast extract, soybean meal, etc., as nitrogen sources are particularly effective. In addition, potassium phosphate, magnesium sulfate, table salt, etc., are usually used as inorganic salts.

It is recommended that the culture of the microorganism 15 is carried out in such a medium at 20 to 40°C, preferably 28 to 37°C and at a pH of 5 to 9, preferably 6 to 8 under an aerobic condition.

The contact during the culture of the grown transformant with the starting material is carried out by previously adding the starting material in the medium or appropriately adding the starting 20 material during the culture. The contact can also be carried out, after completion of the culture, by stirring or shaking the collected cells or treated cells and the starting material in a medium or a suitable buffer, if necessary with addition of suitable coenzymes, etc., in a reactor, or by flowing a starting material-containing matter onto 25 immobilized cells.

The case where the transformant and L-lysine are contacted during the culture is taken as an example, and it is more specifically described below. The transformant is inoculated into a medium and cultured, for example, at 20 to 40°C for 12 to 120 hours 30 to obtain a cultuer broth of the strain containing 10^6 to 10^{10} microor-

ganisms as the transformant per ml. The starting material L-lysine as a solution in water or an auxiliary solvent or L-lysine as such without being dissolved is added so that the final concentration may usually be 0.5 to 30 mg/ml, and reaction is carried out usually at 20 to 5 40°C for 18 hours to 7 days, preferably 18 hours to 5 days. Then, homoglutamic acid can be obtained by ordinary purification methods, for example, various ion exchange chromatography using cation exchange resins, anion exchange resins, etc., adsorption chromatography using HP20, etc., precipitation or crystallization utilizing solvents 10 and temperature, and the like.

The shape and addition time of L-lysine to be added is not particularly limited, but preferably L-lysine is used as monohydrochloride in view of solubility, and it can be added at the start of culture or during the culture, e.g. in 1st to 5th day.

15 According to the invention is provided a DNA containing a gene participating in the production of homoglutamic acid which gene converts L-lysine to homoglutamic acid. This DNA is useful in a microbiological production process of homoglutamic acid. According to the invention are also provided a process of producing homoglutamic acid by a transformant capable of producing homoglutamic acid efficiently, and its use.

20 Hereinafter, the invention is further detailedly described by specific examples. These specific examples are provided for facilitating the understanding of the invention, and it is not intended 25 to restrict the invention to them.

Example 1

Cloning of a gene encoding a protein having dehydrogenase activity, etc.

1. Obtention of a homoglutamic acid-not producing strain

F. lutescens IFO 3084 strain was inoculated into 3 ml of L medium (1.0 % polypeptone, 0.5 % yeast extract, 0.5 % NaCl, 0.1 % glucose, pH 7.2), and shaking cultured at 32°C overnight. 100 μ l of the culture broth as an inoculum was inoculated into 50 ml of L medium, and shaking cultured at 32°C for 4.5 hours. The cells were collected from this culture broth by centrifugation of 5,000 \times g for 10 minutes, washed once with 0.2 M phosphate buffer (pH 6.0), and suspended in 6 ml of 0.2 M phosphate buffer (pH 6.0). 50 μ l of 80 mg/ml NTG was added to this cell suspension, and shaking culture was carried out at 32°C for 20 minutes. Cells collected from this culture broth were washed once with 0.2 M phosphate buffer (pH 6.0), and the whole amount was inoculated into 50 ml of L medium and shaking cultured at 32°C overnight. 500 μ l portions of this culture broth were poured, respectively, 500 μ l portions of 60 % glycerol solution were added, and the mixtures were well mixed, respectively, and then freeze stored at -70°C. The freeze stored mixtures are referred to as mutant storage suspensions.

This mutant storage suspension was 10^6 -fold diluted with 0.85 % NaCl, and 100 μ l portions of the dilution were smeared on MEM agar media (0.5 % polypeptone, 0.2 % yeast extract, 1.0 % lysine-HCl, 0.006 % Methylene Blue, 0.04 % eosin Y and 1.5 % agar, pH 7.2) in 8-cm Petri dishes, and culture was carried out at 32°C for 3 days. White colonies among the grown colonies were inoculated into 1 ml portions of a screening medium (1.0 % polypeptone, 0.2 % yeast extract, 1.0 % lysine-HCl, pH 7.2), and shaking cultured at 32°C for 2 days. 3 μ l of each culture was transferred to a silica gel TLC plate, and dried. This plate was developed with a solvent system consisting of butanol, acetic acid and water (3:1:1), and subjected to ninhydrin coloring, and thereby each lane was checked for the presence or

absence of homoglutamic acid. Thus, from the mutants were separated the first mutant (FERM BP-6799) not producing homoglutamic acid at all, and the second mutant (FERM BP-6798) and the third mutant producing just a bit amount of homoglutamic acid. The 5 results obtained by checking these mutants for the ability of conversion of L-lysine to homoglutamic acid (or productivity of homoglutamic acid) by TLC analysis are shown in Figure 1. In Figure 1, homoglutamic acid is represented by HG (this is also the case with other drawings). The results of assay of LAT activity on these 10 mutants are shown in Figure 2.

2. Construction of a host-vector system and a transformation system

F. lutescens IFO 3084 strain was inoculated into 3 ml of L medium, and shaking cultured at 32°C overnight. 100 µl of the culture broth as an inoculum was inoculated into 50 ml of L medium, and 15 shaking cultured at 32°C for 4.5 hours. The cells were collected from this culture broth by centrifugation of 5,000×g for 10 minutes, washed once with 10 % glycerol solution, and suspended in 3 ml of 10 % glycerol solution. 200 µl portions of this suspension were poured, and freeze stored at -70°C. The freeze stored suspensions are referred to 20 as Electrocell storage suspensions. This storage suspension was thawed on ice, and 1 µl of a solution of 200 µg/ml of Broad Host Range Vector pBBR122 (Mo Bi Tec incorporation) in TE was added. The mixture was put in 0.2-cm Electrocuvette (BIORAD incorporation), electric pulse was once given under a condition of 2.4 kV, 200 Ω and 25 25 µF using Gene Pulser II (BIORAD incorporation). Then the cells were put in a Falcon tube, 1 ml of ice-cooled L medium was added, and shaking culture was carried out at 32°C for 2 hours. The culture broth was smeared on L agar medium (1.0 % polypeptone, 0.5 % yeast extract, 0.5 % NaCl, 0.1 % glucose, 1.5 % agar, pH 7.2) containing 20 30 µg/ml kanamycin, and cultured at 32°C for 3 days. A transformant of

a number of 2.4×10^5 was obtained.

3. Construction of a plasmid pCF704

A primer having an EcoRI site and a primer having an NcoI site were synthesized (Pharmacia incorporation), and the 5 multicloning site and 95 bp of its neighborhood region of pUC18 were amplified, using Taq polymerase (Pharmacia incorporation) and PCR Thermal Cycler PERSONAL (Takara company). This DNA fragment was digested with restriction enzymes EcoRI and NcoI, and the digested product was ligated to the EcoRI and NcoI sites of pBBR122 10 using Ligation Kit version 2 (Takara company). An E. coli competent cell JM109 (Takara company) was transformed with this reaction mixture, and from the resulting transformant, a plasmid pCF704 was prepared using QIAGEN Plasmid Midi Kit.

4. Construction of a plasmid pCF213

15 The genome DNA of F. lutescens IFO 3084 strain was extracted and purified according to QIAGEN Blood and Cell Culture DNA Kit. This genome DNA was partly decomposed with a restriction enzyme SauIII_AI, and the resulting 6 to 8 kbp fragments were cut out from agarose gel, and DNAs were recovered and purified 20 using Ultrafree C3 Unit 0.45 μ m (Millipore corporation) and dissolved in TE solution. The resulting solution is referred to as Insert DNA solution. On the other hand, pCF704 was digested with a restriction enzyme BamHI, and the digest was dephosphorylated with alkaline phosphatase. The resulting digest and Insert DNA solution were 25 subjected to ligation reaction using Ligation Kit version 2 (Takara company), and the reaction mixture was used as a DNA library.

This DNA library was added to the Electrocell storage suspension of the second mutant, and electric pulse was given. The resulting cells were put in a Falcon tube, 1 ml of ice-cooled L medium 30 was added, and shaking culture was carried out at 32°C for 2 hours.

The whole amount of this culture broth was inoculated into 50 ml of L medium containing 20 μ g/ml kanamycin, and shaking culture was carried out at 32°C for 2 days. 500 μ l portions of the culture broth were poured, respectively, and 500 μ l portions of 60 % glycerol solution were added and well mixed, respectively, and the mixtures were freeze stored at -70°C. The freeze stored mixtures are referred to as complementary strain storage suspensions.

This complementary strain storage suspension was 10^3 -fold diluted with 0.85 % NaCl, and 100 μ l portions of the dilution were smeared on MEM agar media of pH 7.0 (0.5 % polypeptone, 0.2 % yeast extract, 1.0 % lysine-HCl, 0.006 % Methylene Blue, 0.04 % eosin Y and 1.5 % agar, pH 7.0) in 8-cm Petri dishes, and culture was carried out at 32°C for 3 days. The black parts of the cells grown on the whole surfaces are referred to as complementary strain mixture cells. The respective complementary strain mixture cells were inoculated into 3 ml portions of the screening medium, and shaking cultured at 32°C for 2 days. 3 μ l portions of each of the culture broths were added dropwise on each lane of a silica gel TLC plate, and dried. This plate was developed with a solvent system consisting of butanol, acetic acid and water (3:1:1), and subjected to ninhydrin coloring, and thereby each lane was checked for the presence or absence of homoglutamic acid. Thus, complementary strain mixture cells recovering homoglutamic acid-producing ability were selected and separated into single colonies, and strains recovering homoglutamic acid-producing ability were selected, and they were referred to as complementary strains. One of plasmids prepared from these complementary strains using QIAGEN Plasmid Midi Kit was named pCF213. About 6.5 kbp of an insert DNA was inserted into pCF213. Together with the complementarity of a separately obtained plasmid pCE111 on each mutant, the complementarity of the above pCF213 was examined, and

the results are shown in Figure 3.

5. Enhancement of homoglutamic acid-producing ability by pCF213

A strain obtained by transforming a wild type *F. lutescens* IFO 3084 strain with pCF704 was designated Wild pCF 704 strain, and 5 a strain obtained by transforming a wild type *F. lutescens* IFO 3084 strain with pCF213 was designated Wild pCF 213 strain. Each of both strains was inoculated into 3 ml of the screening medium containing 20 μ g/ml kanamycin, and shaking cultured at 32°C overnight. 100 μ l portions of each of the culture broths as inoculums were inoculated 10 into 25 ml portions of a production medium (1.5 % polypeptone, 0.5 % yeast extract, 2.0 % lysine-HCl, pH not adjusted), and shaking cultured at 32°C for 24 hours, 48 hours and 72 hours, respectively. The supernatant of each of the culture broths were assayed for the amount of homoglutamic acid by HPLC. Namely, the culture broth 15 was diluted with distilled water so that the total amino acid concentration got to be on the order of 1,000 mg/L, and 50 μ l of the dilution was transferred to a test tube and concentrated to dryness under reduced pressure. 50 μ l of a solution obtained by mixing phenyl isothiocyanate, triethylamine, ethanol and distilled water in 1:1:7:2 20 was added thereto, and the mixture was stirred to dissolve the residue, left alone at room temperature for 10 minutes, and concentrated to dryness under reduced pressure. The residue was dissolved in 500 μ l of Solution A as the mobile phase of HPLC, and 5 μ l of the solution was injected. The HPLC condition is shown below.

25 Column: TSK-GEL super-ODS 4.6ID \times 50 mm

Mobile phase:

Solution A Mixture of a solution obtained by adjusting 140 mM sodium acetate-0.05 % triethylamine to pH 6.2 with glacial acetic acid : acetonitrile in 1,000 : 40

30

W 005 T 005 S 005 E 005

Solution B 70 % acetonitrile

Flow rate: 2.0 ml/min

Elution condition: gradient of a fixed flow rate, linear
gradient of from 2 % to 40 % of Solution B in from
5 0 to 7 minutes, 100 % of Solution B in more than 7
minutes

Detection: UV 254 nm

Temperature: 40°C

Under these conditions, the retention time of homo-
10 glutamic acid was 1.3 minutes, and that of lysine was 7.7 minutes.

As is seen from the results shown in Figure 4, the wild type
pCF213 strain has homoglutamic acid-producing ability 1.5 times
higher than that of the wild type pCF704 strain.

6. Determination of the gene base sequence of the pCF 213 insert
15 region

The base sequence of the pCF 213 insert region was deter-
mined according to the primer walking method using ABI PRISM
377XL DNA Sequencer (Perkin Elmer corporation). This base se-
quence is shown in SEQ ID NO: 2.

20 The open reading frame (ORF) on the determined base
sequence was determined using the method of Bibb et al.(Gene 30,
157 (1984)). As a result, ORF shown in Figure 5 was found.

7. Analysis of the NotI site of about 2.5 kbp in the pCF213 insert
region

25 Analysis of the NotI site of about 2.5 kbp (the base se-
quence of from 2077 to 4578 in SEQ ID NO: 2) in the pCF213 insert
region was carried out. This NotI site of about 2.5 kbp was cut out
from the agarose gel, and the DNA was recovered and purified using
Ultrafree C3 Unit 0.45 μ m (Millipore corporation) and dissolved in TE
30 solution, and the termini were blunted according to DNA Blunting Kit

(Takara company), and the resulting solution was referred to as Insert DNA solution. On the other hand, pCF704 was digested with a restriction enzyme HincII and then dephosphorylated with alkaline phosphatase. This and Insert DNA solution were subjected to ligation 5 reaction using Ligation Kit version 1 (Takara company). F. lutescens IFO 3084 strain was transformed with this reaction mixture, and a plasmid pCF235 was prepared from the transformant using QUI-AGEN Plasmid Midi Kit.

The first mutant transform with pCF235 was inoculated 10 into 3 ml of the screening medium, and shaking cultured at 32°C for 2 days. 3 μ l portions of this culture broth were added dropwise on each lane of TLC silica gel plate and dried. This plate was developed with a solvent system consisting of butanol, acetic acid and water (3:1:1) and subjected to ninhydrin coloring, and each lane was checked for the 15 presence or absence of homoglutamic acid. As a result, it was revealed that the first mutant transformed with pCF235 recovered homoglutamic acid-producing ability.

In the DNA sequence of about 2.5 kbp integrated into pCF235 was present an ORF encoding 510 amino acids starting from 20 ATG of 2855th of the base sequence of SEQ ID NO: 2 and ending in TAA of 4387th. This amino acid sequence was subjected to homology search by BLAST, and as a result, showed high homology with various aldehyde dehydrogenases, and further showed high homology with the amino acid sequence of piperidine-6-carboxylic acid dehydrogenase of 25 Streptomyces davuligerus lately registered with database (J. Bac., Vol.180, No.17, 4753-4756 (1998)) over the whole amino acid sequence. Taking it into account that the first mutant transformed with pCF235 recovered homoglutamic acid-producing ability and that the homoglutamic acid-producing ability of the wild type pCF213 strain was 30 heightened, the protein encoded by this ORF can be regarded as

having piperidine-6-carboxylic acid dehydrogenase.

Example 2

Cloning of a gene encoding a protein having LAT activity, etc.

1. Assay of LAT activity

5 Lysine-HCl (73 mg) and 59 mg of 2-ketoglutaric acid were dissolved in 1 ml of 0.2 M phosphate buffer (pH 7.3) containing 0.5 mM pyridoxal phosphate, and the solution was referred to as reaction solution. The reaction solution (28.75 μ l) was added to 260 μ l of the enzyme solution, and the mixture was left alone at 32°C for 1 hour.

10 151.8 μ l of a solution of 5 % trichloroacetic acid in ethanol was added to discontinue the reaction, the reaction mixture was centrifuged, 90 μ l of 0.2 M phosphate buffer (pH 7.3) containing 4 mM o-aminobenzaldehyde was added to 60 μ l of the supernatant, and the mixture was left alone at 37°C for 1 hour. The mixture was assayed for A465, and

15 the fractions having relatively high A465 were referred to as LAT active fractions.

2. Culture of strain

E. lutescens IFO 3084 strain was shaking cultured at 32°C overnight. The culture broth (50 ml) as an inoculum was inoculated 20 into 10 L of flavo-M9 medium (0.6 % Na_2HPO_4 , 0.3 % KH_2PO_4 , 0.1 % NH_4Cl , 0.2 % NaCl, 1.0 % polypeptone, 0.5 % yeast extract, 0.5 % lysine-HCl, 0.005 % silicone KM75, 0.025 % MgSO_4 , 0.0015 % CaCl_2 , pH 7.2) in 30 L jar fermenter, and aeration stirring cultured for 17 hours. The resulting culture broth (5 L) was centrifuged (1,000 \times g, 10 25 minutes) to collect the cells, and the cells were washed twice with 0.01 M phosphate buffer (pH 7.2). The cells were suspended in the same buffer and subjected to ultrasonic fracture. The fractured cells were removed by centrifugation (1,000 \times g, 10 minutes) to obtain a cell extract. The cell extract was ultracentrifuged (16,000 \times g, 90 minutes), and the supernatant fraction was subjected to the following

purification operations.

3. Purification of enzyme

All the following purification operations were carried out at 4°C, unless otherwise noted.

5 (1) Ammonium sulfate fractionation

The supernatant fraction (600 ml) obtained in Example 1 was purified by ammonium sulfate precipitation. The precipitates formed in the fractions of from 30 % saturation to 80 % saturation were collected by centrifugation (1,000×g, 30 minutes), and dissolved 10 in 0.01 M phosphate buffer (pH 7.2), and the solution was dialyzed against the same buffer.

(2) Desalting

The dialyzed enzyme solution (10 ml) was poured on 4 PD10 columns (Amasham Pharmacia) and eluted and desalted with 15 0.1 M Tris-HCl buffer (pH 7.4) containing 0.5 mM pyridoxal phosphate.

(3) QAE-TOYOPEAL550C column chromatography

The desalted enzyme solution was poured on QAE-TOYOPEAL550C (TOSOH) column (φ 5.5×6.0 cm) previously equilibrated with 0.1 M Tris-HCl buffer (pH 7.4) containing 0.5 mM pyridoxal phosphate, washed with the same buffer, and eluted by 2 L of sodium chloride linear gradient (0 to 1.0 M) using the same buffer, and LAT active fractions were collected.

(4) Phenyl-TOYOPERL650S column chromatography

25 1 M ammonium sulfate was added to the LAT active fractions, and the mixture was poured on Phenyl-TOYOPERL650S (TOSOH) column (φ 5.5×3.0 cm) previously equilibrated with 0.01 M phosphate buffer (pH 7.2) containing 0.5 mM pyridoxal phosphate and 1 M ammonium sulfate, and eluted with 1,200 ml of ammonium 30 sulfate gradient (0.8 to 0 M) using the same buffer, and LAT active

fractions were collected.

(5) Ultrafiltration

The LAT active fractions (150 ml) were ultrafiltered with ADVANTEC UP-20 to make the volume 15 ml. This concentrate (2.5 ml) was poured on PD10 column (Amasham Pharmacia), and eluted and desalting with 0.1 M Tris-HCl buffer (pH 7.4).

(6) AKTA MonoQ HR5/5 column chromatography

The desalting enzyme solution (3.5 ml) was poured on MonoQ HR5/5 column of AKTAexplorer 10S System (Amasham Pharmacia) previously equilibrated with 0.1 M Tris-HCl buffer (pH 7.4), washed with the same buffer, and eluted with 40 ml of sodium chloride linear gradient (0 to 0.4 M) using the same buffer, and LAT active fractions were collected. The LAT active fractions (5 ml) were desalting with PD10 column, and subjected to MonoQ HR5/5 column of AKTAexplorer 10S System, and LAT active fractions were collected. Relations between each fraction and relative LAT activity are shown in Figure 6.

(7) Electrophoresis

The LAT active fractions were subjected to Multigel 4/20 and 10/20 (Daiichi Kagaku Yakuhin Co., Ltd.) and Native-PAGE and SDS-PAGE were carried out, and the results are shown in Figure 7. As to the LAT active fractions, a band was observed at a molecular weight of around 100,000 in Native-PAGE and a band was observed at a molecular weight of around 55,000 in SDS-PAGE. A PVDF membrane was blotted with the band of a molecular weight of around 55,000 in SDS-PAGE using PhastTransfer (Amasham Pharmacia).

4. Analysis of N-terminus amino acid sequence

Analysis of N-terminus amino acid sequence of the band subjected to the blotting was carried out by Edman degradation method using HP G1005A Protein Sequencing System (HEWLETT

PACKARD). As a result, it was revealed that the N-terminus amino acid sequence was

SLLAPLAPLRAHAGTRLTQG.

Based on this, DNA primers

5 NmaRout CCYTGIGTIARICKIGTICCGCRTGIGCICG
NmaRin CCIGCRTGIGCICGIARIGGIGCIARIGGIGC
were designed, and PCR was carried out on the genome DNA of E.
lutescens IFO 3084 strain using LA PCR in vitro cloning KIT (Takara
Company). The PCR reaction condition was 30 cycles of 94°C, 30
10 seconds → 55°C, 2 minutes → 72°C, 1 minute. As a result, a PCR
amplification fragment of about 400 bp containing the above terminus
and its upstream region was obtained. Based on this sequence, its
neighborhood region was obtained using PCR. Namely, the genome
DNA of E. lutescens IFO 3084 strain was digested with restriction
15 enzymes PstI and Sall, respectively, and the digests were subjected,
respectively, to self-ligation reaction using Ligation Kit version 2
(Takara Company), and the resulting DNAs were used as template
DNAs.

Based on these template DNAs, DNA primers

20 NIFout ttgatttgag cagattcgca ctgccattt (SEQ ID NO: 3)
NIRout aaggtttcg acaaagtgac catttccca (SEQ ID NO: 4)
were designed, and PCR was carried out using LA Taq (Takara Com-
pany). The PCR reaction condition was 30 cycles of 98°C, 20 seconds
→ 68°C, 6 minutes. As a result, a PCR amplification fragment of
25 about 2 kbp was obtained from the PstI template and a PCR amplifi-
cation fragment of about 8 kbp from the Sall template. The base
sequence was determined by the primer walking method using
ABIPRISM 377XL DNA Sequencer (Perkin Elmer corporation) on
these PCR amplification fragments. This base sequence is shown in
30 SEQ ID NO: 1.

5. Construction of plasmids pCF301 and pCF335

The following DNA primers wherein the PstI sites of base 545 and base 2658 of SEQ ID NO: 1 were converted to KpnI and SacI sites, respectively,

5 ctgggtaccgc tcatccggc tctgcaccgt (SEQ ID NO: 5)
 ctggagctca ggcaggtgcg ggccacgtgt (SEQ ID NO: 6)

were prepared, and PCR reaction was carried out using these primers to amplify the lat gene region. The amplified fragment of about 2.1 kbp was digested with restriction enzymes KpnI and SacI, and the 10 resulting solution was referred to as Insert DNA solution. On the other hand, pCF704 was digested with restriction enzymes KpnI and SacI, and the digest and Insert DNA solution were subjected to ligation reaction using Ligation Kit version 2 (Takara company), and the resulting plasmid was referred to as pCF301. Further, pCF301 15 was digested with restriction enzymes KpnI and SacI, and the 2.1 kbp fragment was cut out from agarose gel, and this and the digest of pCF235 with restriction enzymes KpnI and SacI were subjected to ligation reaction, and the resulting plasmid was named pCF335.

6. Complementation of LAT activity by plasmid pCF301

20 A mutant obtained by transforming the second mutant with pCF704 was designated 2nd pCF704 strain, and a mutant obtained by transforming the second mutant with pCF301 was designated 2nd pCF301 strain. These strains were shaking cultured at 32°C overnight. Each (30 µl) of the culture broths as an inoculum was 25 inoculated into 3 ml of a production medium (1.5 % polypeptone, 0.5 % yeast extract, 2.0 % lysine-HCl, pH not adjusted) in a centrifugation tube, and aeration stirring cultured for 17 hours. The resulting culture broth (1 ml) was centrifuged (1,000×g, 10 minutes) to collect the cells, and the cells were washed with 10 ml of 0.2 M 30 phosphate buffer (pH 7.3) containing 0.5 mM pyridoxal phosphate.

The cells were suspended in 1 ml of the same buffer and ultrasonically fractured. The fractured cells were removed by centrifugation (1,000×g, 10 minutes) to obtain a cell extract. This cell extract was assayed for LAT activity. The results are shown in Figure 8. pCF301 5 complemented the lat mutation in the second mutant.

7. Heightening of homoglutamic acid-producing ability by pCF335

A transformant obtained by transforming the wild type *E. lutescens* IFO 3084 strain with pCF704 was designated wild type pCF704 strain, and transformants obtained by transforming the IFO 10 3084 strain with plasmids pCF301 and pCF335 were designated wild type pCF301 strain and wild type pCF335 strain, respectively. These strains were inoculated into 3 ml portions of the screening medium containing 20 µg/ml kanamycin, respectively, and shaking cultured at 32°C overnight. 100 µl portions of each of the culture broths as an 15 inoculum were inoculated into 25 ml portions of a production medium (1.5 % polypeptone, 0.5 % yeast extract, 2.0 % lysine-HCl, pH not adjusted), and shaking cultured at 32°C for 24 hours, 48 hours and 72 hours, respectively. The amount of homoglutamic acid in the supernatant of each of the culture broths was measured by HPLC. Namely, 20 each of the culture broths was diluted with distilled water so that the total amino acid concentration could be on the order of 1,000 mg/L, and 50 µl of the dilution was transferred into a test tube and concentrated to dryness. To the residue was added 50 µl of a mixed solution of phenyl isothiocyanate, triethylamine, ethanol and distilled water 25 (1:1:7:2), and the mixture was stirred to make a solution, left alone at room temperature for 10 minutes and concentrated to dryness under reduced pressure. The residue was dissolved in 500 µl of Solution A as a mobile phase of HPLC, and 5 µl thereof was injected. The HPLC condition is as described in 5 of Example 1.

30 As a result, as shown in Figure 9, the wild type pCF335

strain had homoglutamic acid-producing ability about twice higher than that of the wild type pCF704 strain.

CLAIMS

1. An isolated pure DNA containing a gene participating in the production of L-homoglutamic acid, obtainable from a bacterium belonging to Flavobacterium lutescens, or a modifier which hybridizes with the gene under a stringent condition and has a function capable of recovering the L-homoglutamic acid-producing ability of a mutant of Flavobacterium lutescens which lacks the producing ability.

2. The DNA according to claim 1 wherein the gene participating in the production of L-homoglutamic acid is a DNA encoding partly or wholly at least one protein selected from the group consisting of a protein having L-lysine : 2-oxoglutaric acid 6-aminotransferase activity and a protein having piperidine-6-carboxylic acid dehydrogenase activity.

3. The DNA according to claim 2 wherein the DNA encoding the protein having L-lysine : 2-oxoglutaric acid 6-aminotransferase activity is a DNA containing the continuous base sequence from base 801 to base 2276 of SEQ ID NO: 1.

4. The DNA according to claim 3 having the base sequence of SEQ ID NO: 1 or the continuous base sequence from base 545 to base 2658 of SEQ ID NO: 1.

5. The DNA according to claim 2 wherein the DNA encoding the protein having piperidine-6-carboxylic acid dehydrogenase activity is a DNA containing the continuous base sequence from base 2855 to base 4387 of SEQ ID NO: 2.

6. The DNA according to claim 5 having the base sequence of SEQ ID NO: 2 or the continuous base sequence from base 2077 to base 4578 of SEQ ID NO: 2.

7. An autonomously replicative or integration replicative recombinant plasmid carrying the DNA according to claim 1.

8. The recombinant plasmid according to claim 7 having the continuous base sequence from base 545 to base 2658 of SEQ ID NO: 1 and/or the continuous base sequence from base 2077 to base 4578 of SEQ ID NO: 2.

9. The recombinant plasmid according to claim 7 which can be obtained from Flavobacterium lutescens IFO 3084 (pCF213) (FERM BP-6797).

10. A transformant obtained by transforming a bacterium belonging to the genus Flavobacterium as a host with the recombinant plasmid according to claim 7.

11. A process for producing L-homoglutamic acid which comprises culturing in a medium a transformant obtained by transformation with an autonomously replicative or integration replicative recombinant plasmid carrying an isolated pure DNA containing a gene participating in the production of L-homoglutamic acid, obtainable from a bacterium belonging to Flavobacterium lutescens, or a modifier which hybridizes with the gene under a stringent condition and has a function capable of recovering the L-homoglutamic acid-producing ability of a mutant of Flavobacterium lutescens which lacks the producing ability; during or after the culture, contacting the grown transformant with L-lysine or 1-piperidine-6-carboxylic acid to convert it to L-homoglutamic acid; and recovering the thus produced L-homoglutamic acid.

12. The process for producing L-homoglutamic acid according to claim 11 wherein the gene participating in the production of L-homoglutamic acid is a DNA encoding partly or wholly at least one protein selected from the group consisting of a protein having L-lysine : 2-oxoglutaric acid 6-aminotransferase activity and a protein having piperidine-6-carboxylic acid dehydrogenase activity.

13. The process for producing L-homoglutamic acid according

to claim 12 wherein the DNA encoding the protein having L-lysine : 2-oxoglutaric acid 6-aminotransferase activity is a DNA containing the continuous base sequence from base 801 to base 2276 of SEQ ID NO: 1.

14

14. The process for producing L-homoglutamic acid according to claim 12 wherein the DNA encoding the protein having piperidine-6-carboxylic acid dehydrogenase activity is a DNA containing the continuous base sequence from base 2855 to base 4387 of SEQ ID NO: 2.

15

15. The process for producing L-homoglutamic acid according to claim 11 wherein the transformant is one obtained by transforming a bacterium belonging to the genus Flavobacterium as a host with a recombinant plasmid which can be obtained from Flavobacterium lutescens IFO 3084 (pCF213) (FERM BP-6797).

卷之三

09/762230

Fig. 1




Fig. 2




Fig. 3





Fig. 4



09/762230

Fig. 5





Fig. 6



09/762230

Fig. 7






Fig. 8



09/762230

Fig. 9



DECLARATION AND POWER OF ATTORNEY FOR U.S. PATENT APPLICATION

Original Supplemental Substitute PCT Design

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I verily believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Title: GENE PARTICIPATING IN THE PRODUCTION OF HOMOGLUTAMIC ACID AND
ITS USE

of which is described and claimed in:

the attached specification, or
 the specification in the application Serial No. _____ filed _____;
 and with amendments through _____ (if applicable), or
 the specification in International Application No. PCT/ JP99/04197, filed August 4, 1999, and as amended
 on _____ (if applicable).

I hereby state that I have reviewed and understand the content of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge my duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim priority benefits under Title 35, United States Code, §119 (and §172 if this application is for a Design) of any application(s) for patent or inventor's certificate listed below and have also identified below any application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

COUNTRY	APPLICATION NO.	DATE OF FILING	PRIORITY CLAIMED
Japan	232,382/98	August 5, 1998	Yes
Japan	182,362/99	June 28, 1999	Yes

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

APPLICATION SERIAL NO.	U.S. FILING DATE	STATUS: PATENTED, PENDING, ABANDONED

And I hereby appoint John T. Miller, Reg. No. 21,120; Michael R. Davis, Reg. No. 25,134; Matthew M. Jacob, Reg. No. 25,154; Jeffrey Nolton, Reg. No. 25,408; Warren M. Cheek, Jr., Reg. No. 33,367; Nils E. Pedersen, Reg. No. 33,145 and Charles R. Watts, Reg. No. 33,142, who together constitute the firm of WENDEROTH, LIND & PONACK, L.L.P., attorneys to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected therewith.

I hereby authorize the U.S. attorneys named herein to accept and follow instructions from ODAJ IMA & CO. as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and myself. In the event of a change in the persons from whom instructions may be taken, the U.S. attorneys named herein will be so notified by me.

Send Correspondence to

Direct Telephone Calls to:

WENDEROTH, LIND & PONACK, L.L.P.
2033 K Street, N.W., Suite 800
Washington, DC 20006

WENDEROTH, LIND & PONACK, L.L.P.
Area Code (202) 721-8200

Direct Facsimile Messages to:
Area Code (202) 721-8250

Full Name of First Inventor	FAMILY NAME <u>FUJII</u>	FIRST GIVEN NAME <u>Tadashi</u>	SECOND GIVEN NAME	
Residence & Citizenship	CITY <u>Fujisawa-shi</u>	STATE OR COUNTRY <u>Kanagawa-ken</u>	COUNTRY OF CITIZENSHIP <u>Japan</u> <u>JPL</u>	
Post Office Address	ADDRESS <u>7-37-2-215, Syonandai, JAPAN</u>	CITY <u>Fujisawa-shi</u>	STATE OR COUNTRY <u>KANAGAWA</u>	ZIP CODE <u>252-0804</u>
Full Name of Second Inventor	FAMILY NAME <u>NARITA</u>	FIRST GIVEN NAME <u>Takao</u>	SECOND GIVEN NAME	
Residence & Citizenship	CITY <u>Zama-shi</u>	STATE OR COUNTRY <u>Kanagawa-ken</u>	COUNTRY OF CITIZENSHIP <u>Japan</u> <u>JPL</u>	
Post Office Address	ADDRESS <u>4-2-42-312, Minamikurihara, JAPAN</u>	CITY <u>Zama-shi</u>	STATE OR COUNTRY <u>KANAGAWA</u>	ZIP CODE <u>228-0015</u>
Full Name of Third Inventor	FAMILY NAME <u>NAKATA</u>	FIRST GIVEN NAME <u>Kuniho</u>	SECOND GIVEN NAME	
Residence & Citizenship	CITY <u>Fujisawa-shi</u>	STATE OR COUNTRY <u>Kanagawa-ken</u>	COUNTRY OF CITIZENSHIP <u>Japan</u> <u>JPL</u>	
Post Office Address	ADDRESS <u>1-8-10, Tateishi, Fujisawa-shi, JAPAN</u>	CITY <u>Fujisawa-shi</u>	STATE OR COUNTRY <u>KANAGAWA</u>	ZIP CODE <u>251-0872</u>
Full Name of Fourth Inventor	FAMILY NAME <u>AGEMATU</u>	FIRST GIVEN NAME <u>Hitosi</u>	SECOND GIVEN NAME	
Residence & Citizenship	CITY <u>Hadano-shi</u>	STATE OR COUNTRY <u>Kanagawa-ken</u>	COUNTRY OF CITIZENSHIP <u>Japan</u> <u>JPL</u>	
Post Office Address	ADDRESS <u>3-2-1-419, Minamigaoka, JAPAN</u>	CITY <u>Hadano-shi</u>	STATE OR COUNTRY <u>KANAGAWA</u>	ZIP CODE <u>257-0013</u>

Full Name of Fifth Inventor <i>5-00</i>	FAMILY NAME <u>TSUNEKAWA</u>	FIRST GIVEN NAME <u>Hiroshi</u>	SECOND GIVEN NAME
Residence & Citizenship	CITY <u>Fujisawa-shi</u>	STATE OR COUNTRY <u>Kanagawa-ken</u>	COUNTRY OF CITIZENSHIP <u>Japan</u> <i>JPL</i>
Post Office Address	ADDRESS <u>1-2-7-1105, Tsujidoshinmachi, Fujisawa-shi, KANAGAWA 251-0042 JAPAN</u>	CITY STATE OR COUNTRY ZIP CODE	<u>KANAGAWA</u>
Full Name of Sixth Inventor <i>6-00</i>	FAMILY NAME <u>ISSHIKI</u>	FIRST GIVEN NAME <u>Kunio</u>	SECOND GIVEN NAME
Residence & Citizenship	CITY <u>Zama-shi</u>	STATE OR COUNTRY <u>Kanagawa-ken</u>	COUNTRY OF CITIZENSHIP <u>Japan</u> <i>JPL</i>
Post Office Address	ADDRESS <u>2-2-17, Minamikurihara, Zama-shi, KANAGAWA 228-0015 JAPAN</u>	CITY STATE OR COUNTRY ZIP CODE	<u>KANAGAWA</u>
Full Name of Seventh Inventor <i>7-00</i>	FAMILY NAME <u>YOSHIOKA</u>	FIRST GIVEN NAME <u>Takeo</u>	SECOND GIVEN NAME
Residence & Citizenship	CITY <u>Ayase-shi</u>	STATE OR COUNTRY <u>Kanagawa-ken</u>	COUNTRY OF CITIZENSHIP <u>Japan</u> <i>JPL</i>
Post Office Address	ADDRESS <u>1782-10, Yoshioka, Ayase-shi, KANAGAWA 252-1124 JAPAN</u>	CITY STATE OR COUNTRY ZIP CODE	<u>KANAGAWA</u>

I further declare that all statements made herein of my own knowledge are true, and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1st Inventor Tadashi Fujii Date January 25, 2001
 2nd Inventor Takao Norita Date January 25, 2001
 3rd Inventor Kuniyo Nakata Date January 25, 2001
 4th Inventor Nitozi Ageno Date January 25, 2001
 5th Inventor Hiroshi Tsunekawa Date January 25, 2001
 6th Inventor Kunio Isshiki Date January 25, 2001
 7th Inventor Takeo Yoshioka Date January 25, 2001

The above application may be more particularly identified as follows:

U.S. Application Serial No. _____ Filing Date _____
 Applicant Reference Number _____ Atty Docket No. _____
 Title of Invention _____

DECLARATION AND POWER OF ATTORNEY FOR U.S. PATENT APPLICATION

Original Supplemental Substitute PCT Design

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I verily believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Title: GENE PARTICIPATING IN THE PRODUCTION OF HOMOGLUTAMIC ACID AND ITS USE

of which is described and claimed in:

the attached specification, or
 the specification in the application Serial No. _____ filed _____;
 and with amendments through _____ (if applicable), or
 the specification in International Application No. PCT/ JP99/01197, filed August 4, 1999, and as amended on _____ (if applicable).

I hereby state that I have reviewed and understand the content of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge my duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim priority benefits under Title 35, United States Code, §119 (and §172 if this application is for a Design) of any application(s) for patent or inventor's certificate listed below and have also identified below any application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

COUNTRY	APPLICATION NO.	DATE OF FILING	PRIORITY CLAIMED
Japan	232,382/98	August 5, 1998	Yes
Japan	182,362/99	June 28, 1999	Yes

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

APPLICATION SERIAL NO.	U.S. FILING DATE	STATUS: PATENTED, PENDING, ABANDONED

And I hereby appoint John T. Miller, Reg. No. 21,120; Michael R. Davis, Reg. No. 25,134; Matthew M. Jacob, Reg. No. 25,154; Jeffrey Nolton, Reg. No. 25,408; Warren M. Cheek, Jr., Reg. No. 33,367; Nils E. Pedersen, Reg. No. 33,145 and Charles R. Watts, Reg. No. 33,142, who together constitute the firm of WENDEROTH, LIND & PONACK, L.L.P., attorneys to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected therewith.

7

ODAJIMA & CO.

I hereby authorize the U.S. attorneys named herein to accept and follow instructions from _____ as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and myself. In the event of a change in the persons from whom instructions may be taken, the U.S. attorneys named herein will be so notified by me.

Send Correspondence to

Direct Telephone Calls to:

WENDEROTH, LIND & PONACK, L.L.P.
2033 K Street, N.W., Suite 800
Washington, DC 20006

WENDEROTH, LIND & PONACK, L.L.P.
Area Code (202) 721-8200

Direct Facsimile Messages to:
Area Code (202) 721-8250

Full Name of First Inventor	FAMILY NAME <u>FUJII</u>	FIRST GIVEN NAME <u>Tadashi</u>	SECOND GIVEN NAME	
Residence & Citizenship	CITY <u>Fujisawa-shi</u>	STATE OR COUNTRY <u>Kanagawa-ken</u>	COUNTRY OF CITIZENSHIP <u>Japan</u> JPX	
Post Office Address	ADDRESS <u>7-37-2-215, Syonandai, Fujisawa-shi, KANAGAWA</u>	CITY <u>Fujisawa-shi</u>	STATE OR COUNTRY <u>KANAGAWA</u>	ZIP CODE <u>252-0804</u>
Full Name of Second Inventor	FAMILY NAME <u>NARITA</u>	FIRST GIVEN NAME <u>Takao</u>	SECOND GIVEN NAME	
Residence & Citizenship	CITY <u>Zama-shi</u>	STATE OR COUNTRY <u>Kanagawa-ken</u>	COUNTRY OF CITIZENSHIP <u>Japan</u> JPX	
Post Office Address	ADDRESS <u>4-2-42-312, Minamikurihara, Zama-shi, KANAGAWA</u>	CITY <u>Zama-shi</u>	STATE OR COUNTRY <u>KANAGAWA</u>	ZIP CODE <u>228-0015</u>
Full Name of Third Inventor	FAMILY NAME <u>NAKATA</u>	FIRST GIVEN NAME <u>Kuniho</u>	SECOND GIVEN NAME	
Residence & Citizenship	CITY <u>Fujisawa-shi</u>	STATE OR COUNTRY <u>Kanagawa-ken</u>	COUNTRY OF CITIZENSHIP <u>Japan</u> JPX	
Post Office Address	ADDRESS <u>1-8-10, Tateishi, Fujisawa-shi, KANAGAWA</u>	CITY <u>Fujisawa-shi</u>	STATE OR COUNTRY <u>KANAGAWA</u>	ZIP CODE <u>251-0872</u> JAPAN
Full Name of Fourth Inventor	FAMILY NAME <u>AGEMATU</u>	FIRST GIVEN NAME <u>Hitosi</u>	SECOND GIVEN NAME	
Residence & Citizenship	CITY <u>Hadano-shi</u>	STATE OR COUNTRY <u>Kanagawa-ken</u>	COUNTRY OF CITIZENSHIP <u>Japan</u> JPX	
Post Office Address	ADDRESS <u>3-2-1-419, Minamigaoka, Hadano-shi, KANAGAWA</u>	CITY <u>Hadano-shi</u>	STATE OR COUNTRY <u>KANAGAWA</u>	ZIP CODE <u>257-0013</u>

Full Name of Fifth Inventor	FAMILY NAME TSUNEKAWA	FIRST GIVEN NAME Hiroshi	SECOND GIVEN NAME
Residence & Citizenship	CITY Fujisawa-shi	STATE OR COUNTRY Kanagawa-ken	COUNTRY OF CITIZENSHIP Japan
Post Office Address	ADDRESS 1-2-7-1105, Tsujidoshinmachi, Fujisawa-shi, KANAGAWA 251-0042 JAPAN	CITY STATE OR COUNTRY ZIP CODE	STATE OR COUNTRY KANAGAWA ZIP CODE
Full Name of Sixth Inventor	FAMILY NAME ISSHIKI	FIRST GIVEN NAME Kunio	SECOND GIVEN NAME
Residence & Citizenship	CITY Zama-shi	STATE OR COUNTRY Kanagawa-ken	COUNTRY OF CITIZENSHIP Japan
Post Office Address	ADDRESS 2-2-17, Minamikurihara, Zama-shi, KANAGAWA JAPAN	CITY STATE OR COUNTRY ZIP CODE	STATE OR COUNTRY KANAGAWA 228-0015 ZIP CODE
Full Name of Seventh Inventor	FAMILY NAME YOSHIOKA	FIRST GIVEN NAME Takeo	SECOND GIVEN NAME
Residence & Citizenship	CITY Ayase-shi	STATE OR COUNTRY Kanagawa-ken	COUNTRY OF CITIZENSHIP Japan
Post Office Address	ADDRESS 1782-10, Yoshioka, Ayase-shi, KANAGAWA 252-1124 JAPAN	CITY STATE OR COUNTRY ZIP CODE	STATE OR COUNTRY JAPAN ZIP CODE

I further declare that all statements made herein of my own knowledge are true, and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1st Inventor Tadashi Fujii Date January 25, 2001
 2nd Inventor Takao Narita Date January 25, 2001
 3rd Inventor Kunio Nakata Date January 25, 2001
 4th Inventor Kitaoi Ageno Date January 25, 2001
 5th Inventor Hiroshi Tsunekawa Date January 25, 2001
 6th Inventor Kunio Isshiki Date January 25, 2001
 7th Inventor Takeo Yoshioka Date January 25, 2001

The above application may be more particularly identified as follows:

U.S. Application Serial No. _____ Filing Date _____
 Applicant Reference Number _____ Atty Docket No. _____
 Title of Invention _____

SEQUENCE LISTING

<110> FUJII, et al., Tadashi

<120> Gene participating in the production of homoglutamic acid and its use

<130> K-38 Mercian

<140>

<141>

<150> JP10/232382

<151> 1998-08-05

<150> JP11/182362

<151> 1999-06-28

<160> 6

<170> PatentIn Ver. 2.0

<210> 1

<211> 2663

<212> DNA

<213> Flavobacterium lutescens

<220>

<221> CDS

<222> (801)..(2276)

<400> 1

cccggtgtc attgaataacc agcaggtcgc caggttgcag cagctggtcc agatcgcgca 60

cctggcgatc ctccagcgca gccgggtgccc gcggcaccag cagcaggcgg ctggccgaac 120

gctccggcag cggcgccctgg gcaatcagtt cgggaggcag gtggtaggc aaatcgact 180

tcttcaacgc cggcagctcg atacaacggg ggcgtcagtt tacgcccctg taccgcctgt 240

gccctcaccg ctcgaacttg gtgccagga tcaccgccgt ggtgggtgcgc tcgaccccat 300

cagtggcgcc gatggcatcg gtcagctcg ccatacgccgc cacgccatcg acggcggcca 360
 tcgcccaccag gtcatgcgca ccactgaccg aatgcaggct gcgcaccgca gcaatggcct 420
 gcagcgcccg cacgaccgccc ggcattttct tcggcatcac ggtgatggag atatgcgcgc 480
 ggacctgctg gcgctccatc gcctggccaa ggccacgggt gtagccggcg attattccgc 540
 tgtgctgcag ccgctcgatc cggctctgca ccgtggtccg cgacaccccg agccggcg 600
 ccagcgccgc ggtcgaggcg cgccatcct cacgcaacag gtcaagcaac tgtgcacccg 660
 cctggaaat ggtcactttg tcgaaaacct ttcgtcaatc cgccgaaacc ggccattgtat 720
 ttgagcagat tcgcactgcc atttttagtg cgttaacgggt tacaactaac actagacaca 780
 atcagcacgg attcagcatg tcc ctt ctt gcc ccg ctc gcc ccg ctc cgc gcc 833
 Ser Leu Leu Ala Pro Leu Ala Pro Leu Arg Ala
 1 5 10
 cat gcc ggc acc cgc ctt acc cag ggc ctg tct gac ccg cag gtc gag 881
 His Ala Gly Thr Arg Leu Thr Gln Gly Leu Ser Asp Pro Gln Val Glu
 15 20 25
 cag ctg gcc gcc aac cac cct gac ctg cgc gcc gcc atc gac gcc gct 929
 Gln Leu Ala Ala Asn His Pro Asp Leu Arg Ala Ala Ile Asp Ala Ala
 30 35 40
 gcc gac gaa tac gcg cgc atc aaa ccg cag gcc gcg gca ttg ctg gac 977
 Ala Asp Glu Tyr Ala Arg Ile Lys Pro Gln Ala Ala Leu Leu Asp
 45 50 55
 ctg gat gaa agc gcg cag atc gcc gcc gtg cag gat ggc ttc gtc aac 1025
 Leu Asp Glu Ser Ala Gln Ile Ala Ala Val Gln Asp Gly Phe Val Asn
 60 65 70 75
 ttc tat gcc gat gat gcg gtg gtg ccc tat atc gcc ctg gcc gcc cgc 1073
 Phe Tyr Ala Asp Asp Ala Val Val Pro Tyr Ile Ala Leu Ala Ala Arg
 80 85 90

ggg ccg tgg gtg gtc agc ctg aag ggc gcg gtg ctg tat gac gcc ggc	1121
Gly Pro Trp Val Val Ser Leu Lys Gly Ala Val Leu Tyr Asp Ala Gly	
95 100 105	
ggc tac ggc atg ctc ggc ttc ggc cat acc ccg gcc gat atc ctg gag	1169
Gly Tyr Gly Met Leu Gly Phe Gly His Thr Pro Ala Asp Ile Leu Glu	
110 115 120	
gca gtc ggc aag ccg cag gtg atg gcc aac atc atg act ccc tcg ctg	1217
Ala Val Gly Lys Pro Gln Val Met Ala Asn Ile Met Thr Pro Ser Leu	
125 130 135	
gcc cag ggc cgc ttc att gcc gca atg cgc cgc gaa atc ggc cat acc	1265
Ala Gln Gly Arg Phe Ile Ala Ala Met Arg Arg Glu Ile Gly His Thr	
140 145 150 155	
cgc ggc ggc tgc ccg ttc tcg cac ttc atg tgc ctg aac tcc ggc tcc	1313
Arg Gly Gly Cys Pro Phe Ser His Phe Met Cys Leu Asn Ser Gly Ser	
160 165 170	
gaa gca gtc ggg ctg gcc gca atc gac atc aac gcc aag ctg	1361
Glu Ala Val Gly Leu Ala Ala Arg Ile Ala Asp Ile Asn Ala Lys Leu	
175 180 185	
atg acc gac ccg ggc gcc cgg cat gcc ggc acg atc aag cgc gtg	1409
Met Thr Asp Pro Gly Ala Arg His Ala Gly Ala Thr Ile Lys Arg Val	
190 195 200	
gtg atc aag ggc agt ttc cac ggc cgt acc gac cgt ccg ggc ctg tat	1457
Val Ile Lys Gly Ser Phe His Gly Arg Thr Asp Arg Pro Ala Leu Tyr	
205 210 215	
tcc gat tcc acc cgc aag gcc tac gat gca cat ctg gcc agc tac cgc	1505
Ser Asp Ser Thr Arg Lys Ala Tyr Asp Ala His Leu Ala Ser Tyr Arg	
220 225 230 235	
gac gag cac agc gtc att gcc atc gcc ccg tat gac cag cag gcc ctg	1553
Asp Glu His Ser Val Ile Ala Ile Ala Pro Tyr Asp Gln Gln Ala Leu	
240 245 250	

cgc cag gtg ttt gcc gat gcc cag gcc aac cac tgg ttc atc gag gcg	1601
Arg Gln Val Phe Ala Asp Ala Gln Ala Asn His Trp Phe Ile Glu Ala	
255 260 265	
gtg ttc ctg gag ccg gtg atg ggc gaa ggc gac ccg ggc cgt gcg gtg	1649
Val Phe Leu Glu Pro Val Met Gly Glu Gly Asp Pro Gly Arg Ala Val	
270 275 280	
ccg gtg gac ttc tac cgc ctg gcc cgt gag ctg acc cgc gaa cac ggc	1697
Pro Val Asp Phe Tyr Arg Leu Ala Arg Glu Leu Thr Arg Glu His Gly	
285 290 295	
agc ctg ctg ctg atc gat tcg atc cag gcc gcg ctg cgc gtg cac ggc	1745
Ser Leu Leu Leu Ile Asp Ser Ile Gln Ala Ala Leu Arg Val His Gly	
300 305 310 315	
acc ctg tcc ttc gtc gac tac ccc ggc cac cag gag ctg gag gca ccg	1793
Thr Leu Ser Phe Val Asp Tyr Pro Gly His Gln Glu Leu Glu Ala Pro	
320 325 330	
gac atg gag acc tac tcc aag gcc ctg aac ggc gcc cag ttc ccg ctg	1841
Asp Met Glu Thr Tyr Ser Lys Ala Leu Asn Gly Ala Gln Phe Pro Leu	
335 340 345	
tgc gta gtg gcc gtg acc gag cac gcc gcg ctg tac cgc aag ggc	1889
Ser Val Val Ala Val Thr Glu His Ala Ala Leu Tyr Arg Lys Gly	
350 355 360	
gtg tac ggc aac acc atg acc acc aac ccg cgg gcg ctg gac gtg gcc	1937
Val Tyr Gly Asn Thr Met Thr Asn Pro Arg Ala Leu Asp Val Ala	
365 370 375	
tgc gcc acc ctg gca cgc ctg gat gag ccg gtc cgc aac aat atc cgc	1985
Cys Ala Thr Leu Ala Arg Leu Asp Glu Pro Val Arg Asn Asn Ile Arg	
380 385 390 395	
ctg cgt ggc cag cag gcg atg cag aag ctg gaa gca ttg aag gaa cgg	2033
Leu Arg Gly Gln Gln Ala Met Gln Lys Leu Glu Ala Leu Lys Glu Arg	
400 405 410	

ctg ggg ggc gcg atc acc aag gtg cag ggc acc ggc ctg ctg ttc tcc	2081
Leu Gly Gly Ala Ile Thr Lys Val Gln Gly Thr Gly Leu Leu Phe Ser	
415 420 425	
tgc gag ctg gcc ccg cag tac aag tgc tac ggg gcc ggc tcc acc gag	2129
Cys Glu Leu Ala Pro Gln Tyr Lys Cys Tyr Gly Ala Gly Ser Thr Glu	
430 435 440	
gag tgg ctg cgc atg cac ggg gtc aat gtg atc cac ggc ggc gag aat	2177
Glu Trp Leu Arg Met His Gly Val Asn Val Ile His Gly Gly Glu Asn	
445 450 455	
tcg ctg cgc ttc acc ccg cac ttc ggc atg gac gag gcc gaa ctg gac	2225
Ser Leu Arg Phe Thr Pro His Phe Gly Met Asp Glu Ala Glu Leu Asp	
460 465 470 475	
ctg ctg gtg gag atg gtc ggg cgt gcg ctg gtc gaa ggc cca cgc cgg	2273
Leu Leu Val Glu Met Val Gly Arg Ala Leu Val Glu Gly Pro Arg Arg	
480 485 490	
gcc tga tccgcacccg caggacggaa ggcacgagcc caccgtgagg cgggctctt gc	2331
Ala Stop	
tgcccgac cagcgcaac aggccgcgt gtcaccggcc aggccggcg ccggcagtgg	2391
gtttcagccg caggggtccg ccctgccagc gcctgcggcg gggcacaggg ttgcgggcat	2451
tgccgcctct gccacggca cgcagccgga gatcaggctg acaagggggc tgccccgggt	2511
ggcagtagacac gaccagccag ttgactgccg gtattgcctt gatcagcgct gcatccagaa	2571
cagcaccatc ggttgcgtga ctgacgcgcc gctggccgtt gcgggacagc agccttgcg	2631
tcacacgtgg cccgcacctg cctgcactgc ag	2663

<210> 2
 <211> 6357
 <212> DNA
 <213> *Flavobacterium lutescens*

<220>

<221> CDS

<222> (2855)..(4387)

<400> 2

ggatcgggcc actgggctca ctgctggacg caatccgagt gccgggatgg ctcgggttga 60

aggtgttgcg gatcacgatc ggcatctgcc gggcgatggc cgggctcatc gtctgcgggt 120

gcaccacctt ggcgccgaaa taggccagtt cgcaggcctc gtcatacgctg agcgtggcca 180

gggtcacccgc ctcgggcacc acccgcgggt cggccgacag cacaccgtcg acatcggtcc 240

agatgtgcag ctcggccgccc tcgaacagcg cggcaaagat cgccccggaa taatcgctgc 300

cggtgcggcc cagggtgttg atcctgcctt ggccatcacg ggcgacaaaaa ccggtgacca 360

ccacccgcga ctgcgggttg tccacacgcc aggccggccag gttggccgca ctgcgttccc 420

gtcgacgct gaccccccagc tcgccgtgtg cgaccaccag cacatcgccgg gcatcgagca 480

ccgcgcaggg gtggccgagc cgggtgaaat agcggcccag cagctgggcc gagaacacct 540

ccgcggccagccc ctgcaccctt tcaaggcacct cctcgggcag gccggccatc accgccagcg 600

cttccagcaa cccggccagc ttgtcaaagc gtccatccag ccactgcagc aggtcggcag 660

aatcctcgcc cagcagttcg gtggccgctt catggtgttgc ctggcgcagg gcctgccagg 720

catcacgcca ggcgcggctga ccgtggcgg ccagggttagc cagctcgatc aaggcatcg 780

tgacaccctt catcgccgag accaccacca cctgggtggg ttccgggcgc tgcagcagca 840

actcggcgac atggcggtag cgctgcgcgg aggccaccga ggtgccgcgg aacttgtggg 900

cgtatgacccctg ggcacatcgggc gcgggagcgg gagcgggtgc agcggcaggc gatgacatca 960

caacagacccctt ctggggttga ggcccgccac cgcaggttgc gaagtcccgc aacctggtcg 1020

gtgcggggcc gttgtttcg ggggttagac gaatacgacg ggccgcacca gccaaagtgg 1080

ggtgttaatg atggtcatgc cggtgacgcc agcaggcgcc agcagggcgg cagtggaaatc 1140
aacggtggcg cggcagatcg acatgcagcg agcagaccgc acagcgccctg ctgctgtcaa 1200
ctgttgcatt gcaaaataat tttccgcga tcatggcga acatgcacccg atttggttgc 1260
aatgtgatc gtcagcgatc ttctgtcaaa acccgccggat caagcggcca cagccgctgc 1320
ggcagccgcg gaccaccgcg cgccgatgcc agcgccgggc ggcagagcaa gccgcccagcg 1380
caaccggcca ttaccgcggc caggcgccgg gcctgcgcgg ctcaaccgtg gatTTTTcc 1440
cagcgggcgt gggcctgcgc ggccagcacc accccgcccga ccaacagcgc aatggccagc 1500
agctccagca gggtcgggcc acgctgctgc cagatgaagc cataaagcaa cgcgaaacagg 1560
gtttcaaaca cgatcagctg cccgcccagg ctcagcggca ggctgcgcgt ggcccgggttc 1620
cagcaggcat tgcccagcac cgaggcaccg acggccagca gcgcacagat gccggcaaag 1680
tgcagccact ggccctggct ctgcccggc ggccccagcc acagcgccag cggcagcaac 1740
agcacggcga tggccctgt ggccaccccg gtcaacaacg accaggcatg cccggacagg 1800
tgcgatagc gcccgcattca caccacattg gcgatcgagt agccactcca ggccggccagc 1860
gcggccagcg cgagcagcag gcccagcacc cgctgaccga tgtccttgcc agcatcgccc 1920
gccgcgccccg cgccgtggcc gagtgcagcc caggccacca gcagcgagcc cagcacacac 1980
aggcacagcg ccggtgccag ctgacgcaac ggcagggccg ttggccgccc cgcattccacc 2040
gccgccacca ccaccggcac catgcccacg atcagcggcgg ccggccgcacc gccagcccag 2100
tgcacggcca tcgccagaaa cacgaaatag accaggttgc cgagcaggct cagccggcc 2160
agggccagcc aggcgccggcg atcgacctgc gcacgcagcg ccggccacaa cggcagcagc 2220
aacgcacagg ccaccgcacc gtacagcagg tagcggccca cggccagctg cagcgcagaa 2280
aatgcgggtgg tcaaggccgg cgccaggaac accatgcccc acagggcacc ggcgagcagc 2340

cggttgaaca gtccccacgc ggtctgggttgc ttgcgcgttgc tcacgctgca aggcgcgttgc 2400
atgaacaaca ggcggggcg gcgcagcgca tggcgctgg cagctctccg acctgtgca 2460
agggtggtggc cccgacacga ttcgaacgtt cgacctgtcc ctttaggaggg gaccgctcta 2520
tccagctgag ctacggagcc atgaggccgg cgattctagc atccgctctc cgttcacggc 2580
catcgccgc agccgcagtt cacagtgcag ggcaaccgca gcaagccccc gccccgctgc 2640
aaccctcgcg cccgcgcgca acgtgaccgg cgccgcggca ggcccggccc ccacggccac 2700
tggcgccggt tccgcaccac gccaccggca acacgcccccc agccctgccc aacgtggtgt 2760
ttcagcgctc tggtaagatg gcatgcccac atgccacccctc ccccccggacg cgccgcgggt 2820
gcgtgacctt ttctgttacatgt aatctggagt ttcc atg tcg ttt gaa ctg ctc aag 2875
Met Ser Phe Glu Leu Leu Lys
1 5
gcc tta ggg ctg gac gcc acc aat tcc ggc acc tac ctg ggt gat gga 2923
Ala Leu Gly Leu Asp Ala Thr Asn Ser Gly Thr Tyr Leu Gly Asp Gly
10 15 20
gaa tgg tcc agc gct acc ggt gcc ggg acc atc agc ccg cgc aac ccg 2971
Glu Trp Ser Ser Ala Thr Gly Ala Gly Thr Ile Ser Pro Arg Asn Pro
25 30 35
acc acc ggc gag gtc att gcc cag gtc cag gcc acc acc gag ggc gac 3019
Thr Thr Gly Glu Val Ile Ala Gln Val Gln Ala Thr Thr Glu Ala Asp
40 45 50 55
tac gaa acc atc ctg gcc cgc gcc cag cag gcc ttc aag gtc tgg cgc 3067
Tyr Glu Thr Ile Leu Ala Arg Ala Gln Gln Ala Phe Lys Val Trp Arg
60 65 70
acc acc ccg gca ccg cgc cgc ggc gag gcc atc cgc ctg tgt ggc gag 3115
Thr Thr Pro Ala Pro Arg Arg Gly Glu Ala Ile Arg Leu Cys Gly Glu
75 80 85

gcc ctg cgc cgc cac aag gac gcg ctg ggt tcg ctg gtc gcg ctg gaa			3163
Ala Leu Arg Arg His Lys Asp Ala Leu Gly Ser Leu Val Ala Leu Glu			
90	95	100	
atg ggc aag tcc aag ccg gaa ggc gac ggc gaa gtc cag gaa atg atc			3211
Met Gly Lys Ser Lys Pro Glu Gly Asp Gly Glu Val Gln Glu Met Ile			
105	110	115	
gac atc gcc gac ttt gcc gtc ggc cag agc cgc atg ctg tat ggc tac			3259
Asp Ile Ala Asp Phe Ala Val Gly Gln Ser Arg Met Leu Tyr Gly Tyr			
120	125	130	135
acc atg cac agc gag cgc ccc ggc cac cgc atg tac gag cag tac cag			3307
Thr Met His Ser Glu Arg Pro Gly His Arg Met Tyr Glu Gln Tyr Gln			
140	145	150	
ccg ctg ggc atc gtc ggc atc atc tcg gcc ttc aac ttc ccg gtc gcg			3355
Pro Leu Gly Ile Val Gly Ile Ile Ser Ala Phe Asn Phe Pro Val Ala			
155	160	165	
gtc tgg gcc tgg aac agc ttc ctg gcc gcg atc tgt ggt gat gtc tgc			3403
Val Trp Ala Trp Asn Ser Phe Leu Ala Ala Ile Cys Gly Asp Val Cys			
170	175	180	
atc tgg aag ccg tcc aac aag acc ccg ctg acc gcg atc gcg tcc atg			3451
Ile Trp Lys Pro Ser Asn Lys Thr Pro Leu Thr Ala Ile Ala Ser Met			
185	190	195	
cgc atc tgc aac gaa gca ctg cgc gaa ggc ggc ttc ccg gac atc ttc			3499
Arg Ile Cys Asn Glu Ala Leu Arg Glu Gly Gly Phe Pro Asp Ile Phe			
200	205	210	215
ttc ctg atc aac gac gcc ggc acc gcg ttg tcg gag aag ctg gtc gag			3547
Phe Leu Ile Asn Asp Ala Gly Thr Ala Leu Ser Glu Lys Leu Val Glu			
220	225	230	
gac aag cgc gtg ccg ctg atc tcc ttc acc ggc tcg acc cag gtc ggg			3595
Asp Lys Arg Val Pro Leu Ile Ser Phe Thr Gly Ser Thr Gln Val Gly			
235	240	245	

cgc atc gtc aac cag aag gtc gcc gcc cgc ctg ggc cgc tgc ctg ctc			3643
Arg Ile Val Asn Gln Lys Val Ala Ala Arg Leu Gly Arg Cys Leu Leu			
250	255	260	
gag ctg ggc ggc aac aac gcg atc atc ctg gac gaa acc gcc gac ctg			3691
Glu Leu Gly Gly Asn Asn Ala Ile Ile Leu Asp Glu Thr Ala Asp Leu			
265	270	275	
aag ctg gcc gtg ccg ggc atc gtc ttc ggc gcc gtc ggc acc gcc ggc			3739
Lys Leu Ala Val Pro Gly Ile Val Phe Gly Ala Val Gly Thr Ala Gly			
280	285	290	295
cag cgc tgc acc acc acc cgc cgc ctg atc gtg cac gaa tcg atc tac			3787
Gln Arg Cys Thr Thr Arg Arg Leu Ile Val His Glu Ser Ile Tyr			
300	305	310	
gac aac gtg ctg gcc acc ttg atc aag gcc tac aag cag gtc gaa ggc			3835
Asp Asn Val Leu Ala Thr Leu Ile Lys Ala Tyr Lys Gln Val Glu Gly			
315	320	325	
aag atc ggc gat ccg ctg gat gcc gcc aac ctg atg ggc ccg ctc aac			3883
Lys Ile Gly Asp Pro Leu Asp Ala Ala Asn Leu Met Gly Pro Leu Asn			
330	335	340	
gag ccc gaa gcg gtg cag cag ttc ctg gcc tcg atc gag aaa gcc aag			3931
Ser Pro Glu Ala Val Gln Gln Phe Leu Ala Ser Ile Glu Lys Ala Lys			
345	350	355	
gcc gct ggc acc gtt caa acc ggt ggt acc gcg atc gac cgc ccg			3979
Ala Ala Gly Gly Thr Val Gln Thr Gly Gly Thr Ala Ile Asp Arg Pro			
360	365	370	375
ggc aac ttc gtg ctg ccg gcc atc gtc acc ggc ctg aag aac agc gat			4027
Gly Asn Phe Val Leu Pro Ala Ile Val Thr Gly Leu Lys Asn Ser Asp			
380	385	390	
gag gtg gtc cag cac gag acc ttc gcc ccg atc ctg tac gta atg aag			4075
Glu Val Val Gln His Glu Thr Phe Ala Pro Ile Leu Tyr Val Met Lys			
395	400	405	

tac tcc acc ctg gac gaa gcc atc gag atg cag aac ggc gtg ccg cag 4123
Tyr Ser Thr Leu Asp Glu Ala Ile Glu Met Gln Asn Gly Val Pro Gln
410 415 420

ggc ctg tcc tcg tcg atc ttc acc acg aac ctg aag gca gcc gag aag 4171
Gly Leu Ser Ser Ser Ile Phe Thr Thr Asn Leu Lys Ala Ala Glu Lys
425 430 435

ttc ctg tcg gcg gcc ggc agc gac tgc ggc att gcc aac gtc aac atc 4219
Phe Leu Ser Ala Ala Gly Ser Asp Cys Gly Ile Ala Asn Val Asn Ile
440 445 450 455

ggc act tcc ggt gcc gag atc ggc ggc gcc ttc ggt ggc gag aag gaa 4267
Gly Thr Ser Gly Ala Glu Ile Gly Gly Ala Phe Gly Gly Glu Lys Glu
460 465 470

acc ggc ggt ggc cgt gag tcc ggc tcg gat ggc tgg aag gtc tac atg 4315
Thr Gly Gly Arg Glu Ser Gly Ser Asp Ala Trp Lys Val Tyr Met
475 480 485

cgc cgc cag acc aac acc atc aac tac tcc gac tcg ctg ccg ctg gcc 4363
Arg Arg Gln Thr Asn Thr Ile Asn Tyr Ser Asp Ser Leu Pro Leu Ala
490 495 500

gag ggc atc aag ttc gac ctg taa gccgctcgcc acggcccgcc ttcccccggaa 4417
Gln Gly Ile Lys Phe Asp Leu Stop
505 510

gcaggccgtg gctgttgac cagccagagg agtgactgca tgactgcaat tgaatcgact 4477

gccgcacgca ccaccaacac ttgcgcacatc ctgtcgctgg tactggcact gctggcgtgg 4537

aatctttgc cggtgattgg ctttgtcggc gccatcatct gccggccgcat cgcccagcgc 4597

cagctcaagc agcccgccaa tacccaggac ggtcacggcc tggcaagggc gggcatctgg 4657

atcagttgga tcagcctgat cctgggttgcg ctgctgatcg gcgtcgtgat cccgtggttg 4717

accggccccga tcacgatcaa cctgcccgtt tccacctgac cctccctccct gccagtcgcc 4777

catgcgctga caggccaacc cgtttcctgc ctggaccaga ccatgctccc gcccgaccat 4837

ccggctccac catcgccat tgccggcacc acaacctcga ccaatggcta tgcggtggcc 4897
tcgctggtga tggcatacct tggctggtcg atgatcccgc tggatggcag catcgccgccc 4957
atcggttcg ggcatactggc ccgggcgcag atccgtcgcc agcccaagca gggcgatggc 5017
ctggcactgg ccgggctgat cctgggctgg atctcgattt cgctgtggat cctcgggatc 5077
ctggcggttt tcctcttctt tggcgggctg gccatgctgc tcagcctgaa cgcctgaccc 5137
gagccttgcc gtatgttattc cctgctccgt cccgcctgt tctgcatgga tgccgagcgc 5197
gcccattggcg ccggcctgctcg cgcctggat cttgcctacc gcagcggtac gctggggctg 5257
gtggccagcc ggccagcacc gcttccaacc cgcgctttcg gcctggaatt ccccaaccccg 5317
gtgggcctgg cggccggcct ggacaagaac ggcgagcata tcgatgcact gttcgcgctg 5377
gtgtttggct atgtcgaaat cggcacggtg accccgcgcc cgcaaggccgg caatccgcag 5437
ccacggctgt tccgcgtgcc cgagcacctg ggcgtgatca accgcatggg tttcaacaat 5497
ggccggcgctcg atgcgctggt ggccaatgtg cgcgccgcac ggcgtgaccg cggcatcctc 5557
ggcatcaaca tcggcaagaa caaggacacc cccaaacgagc tggccatac cgattacctg 5617
acctgcctgg aaaagggtgt a cgcgctggcc gactacatca ccgtcaacat ctccctgccc 5677
aacaccggccg ggctgcgcga gctgcaggaa gaacaggccc tgcgcgagct ggtcagccgc 5737
ctgcgcgagg gccaggaaac cctggccgca cgccatggca agcgggtgcc gatgctggtc 5797
aaggtcgcgc cggacctgag cgatgccat gtcgatgcgc cgcggcgatgt gctggcagag 5857
ctgcagggtgg acgggggtgat cgccaccaac accaccatcg cgccgtggg catggaaaac 5917
cacccactgg ccagcgaggc cggccggctg tccggggcac cggatggc ggcgtccacc 5977
gcgggtgctgc gccgcgtgcg cacccggctg cggagtcga tcccgctgat cggcgatggc 6037
ggcatctgtt ccggggctga tgcggcgcc aagatgagtg cggcgccgac catggtgca 6097

ctctacagcg ggctggttta ccgcggcccg gcactggtcg gcgaatgcgt cgaatcgatc 6157
cgccgcccgc gCGAAGCGCC ctccagcggg gtagcccatc tgtgagtacg ccgggctggc 6217
agctgcacca cgatgtcgca ctgcaatcaa tgaacacctt cggggtagcg gccaccgcgc 6277
cgccgcctgct gCGCGTGCAC gacagccagg ccctgcccgc ggcgctggcg caccggaaag 6337
tagccggaca gccgttgate 6357

<210> 3
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthesized
considering the base sequence of a PCR
amplification fragment of about 400 bp obtained
based on the N-terminus amino acid sequence
information using LAPCR in vitro cloning KIT

<400> 3
ttgatttgag cagattcgca ctgccattt 29

<210> 4
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthesized
considering the base sequence of a PCR
amplification fragment of about 400 bp obtained
based on the N-terminus amino acid sequence
information using LAPCR in vitro cloning KIT

<400> 4
aaggtttcg accaaagtgac catttccca 29

<210> 5
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthesized
considering sequences obtained by converting the
PstI sites of base 545 and base 2658 of Sequence
table: 1 to PstI and SacI sites, respectively


<400> 5
ctggtaaccgc tcgatccggc tctgcaccgt 30

<210> 6
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthesized
considering sequences obtained by converting the
PstI sites of base 545 and base 2658 of Sequence
table: 1 to PstI and SacI sites, respectively

<400> 6
ctggagctca ggcaggtgcg ggccacgtgt 30

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

Page(s) _____ of _____ were not present
for scanning. (Document title)

Page(s) _____ of _____ were not present
for scanning. (Document title)

Scanned copy is best available.

Some drawing figures are very dark.